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Both cancer and autoimmune diseases have been associated with numerous factors that 
may independently lead to the development of either disease. When these factors overlap 
the difficulty in assessing association is compounded. The numerous factors that are 
thought to cause systemic lupus erythematosus (SLE), which leads to the development of 
cancer, makes the study of an association between the 2 diseases challenging. The 
purpose of this study was to examine whether the risk of cancer development increased in 
SLE patients compared to the risk in non-SLE patients. Researchers have not shown 
consistent relationships of cancer development in patients with SLE; however, 
consideration of the various factors that contribute to the diseases is necessary to measure 
an association between the 2 diseases. This study used the Clinical Practice Research 
database (CPRD), a large, population-based database to test the relationship between SLE 
and cancer. A matched retrospective cohort study among SLE (n=3025) and non-SLE 
(n=180555) patients was conducted using the propensity score methodology to help 
balance the differences between the comparison groups. The propensity score 
methodology created a similar distribution of observed baseline covariates between the 2 
groups. With adjustment for age, the predictor variable of SLE indicates that a patient 
with SLE is still 2.7 times more likely to develop cancer than is a non-SLE patient. The 
study outcomes could promote positive social change by reinforcing current 
recommendations for cancer screenings in persons with SLE, which could enhance the 
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Chapter 1: Introduction to the Study 
Introduction 
Systemic lupus erythematosus (SLE) has accounted for a significant number of 
deaths because of the devastation that this disease causes on numerous organ systems of 
the body. SLE disease activity is better understood and is controlled with the use of 
medications (Liang et al., 2012). The control of SLE flares has resulted in decreased 
deaths due to SLE activity, and people affected by the disease are living longer that they 
did 25 years ago (Liang et al., 2012). However, the increase in the lifespan of people with 
SLE has led researchers to determine that other chronic diseases are often the cause of 
death for persons with SLE (Liang et al., 2012).  
People with SLE are more likely to be diagnosed with certain types of cancer as 
compared to persons without SLE (Bernatsky et al., 2005; Kiss, Kovacs, & Szodoray, 
2010; Parikh-Patel, White, Allen, & Cress, 2008). Several risk factors have been 
proposed to account for the increased development of cancer among persons with SLE, 
including the use of immunosuppressive agents that increases the development of 
malignancies (Bernatsky, Ramsey-Goldman, & Clarke, 2006). Other risk factors that may 
increase the incidence of cancer in people with SLE include genetic predisposition, 
lifestyle-related risk factors, and abnormalities in cell death regulation (Kiss et al., 2010; 
Tincani, Taraborelli, & Cattaneo, 2010; Schultz & Harrington, 2003). In this study, I 




The results of this study may provide a better understanding of cancer 
development in people with SLE. The results did reveal a greater association of cancer 
development in patients with SLE as compared to non-SLE patients. The study outcomes 
could promote positive social change by reinforcing current recommendations for cancer 
screenings particularly in persons with SLE. Stronger adherence to cancer screening 
recommendations could enhance the ability to detect a cancer early enough so that 
treatment can be implemented that may result in a higher likelihood of eradicating the 
cancer and decreasing mortality due to cancer in persons with SLE. The results from this 
study may also equip persons with SLE with scientifically based knowledge that may 
enable them to make decisions regarding their care with a clearer understanding of the 
cancer risks inherent to persons with SLE, particularly when factored with their 
knowledge of their personal familial risks for cancer development.  
In this chapter, literature related to cancer development in persons with SLE is 
summarized to identify gaps in current knowledge. The significance of whether an 
association in cancer development exists in persons with SLE is presented. A discussion 
of the purpose of the study, research questions, and the theoretical framework for the 
study are presented. Both dependent and independent variables and their definitions are 
provided. The research problem addressed and the limitations of the study are described 
in this section. The chapter concludes with potential contributions that this study will 






Several risk factors for the development of cancer among persons with SLE have 
been proposed that would support an increased risk of cancer in this population, but these 
risks have not been fully explored. Both SLE and cancer have etiologic agents in 
common. In assessing the association of cancer in autoimmune diseases, many of the 
treatments used for the treatment of autoimmune diseases have been associated with the 
development of cancer (Azab et al., 2008). In addition, both cancer and autoimmune 
diseases have been associated with diet, air quality, exposure to certain drugs, and 
personal habits, which makes the study of an association between the two diseases 
challenging. Bei, Masuelli, Palumbo, Modesti, and Modesti (2009) concluded that the 
interaction between autoantibodies in cancer patients and autoimmune patients have 
similar antibodies that must be considered because they can change the properties of each 
other and impact the growth and progression of each disease. SLE is an autoimmune 
disease that results when the body starts to produce antibodies against itself. Signaling 
between antibodies (T cells and B cells) is impaired. Both T cells and B cells are 
instrumental in the development of several cancers. The interaction of these two 
antibodies must be considered because the properties of each are interdependent, as 
concluded by Bei et al. (2009).  
Researchers have not consistently shown positive relationships between cancer 
development and SLE. Some scholars have shown that an increased risk of hematological 
cancers in SLE patients is likely because of other causes such as medications (Bernatsky 




disease is necessary to measure an association of the variable to disease development 
(Broadbent, 2009). Because autoimmune diseases, such as SLE, have several risk factors 
that are thought to cause the disease, a more definitive association of the proposed causes 
of SLE are needed to measure better the association of the SLE risk factors in cancer 
development. The use of the high dimensional propensity model in this study balanced 
the two cohorts, so that a better assessment of the selected risk factors can be conducted. 
Previous studies conducted have concluded that cancer rates are increased in SLE 
patients. The previous studies have shown variability in which types of cancers have been 
found to be increased. Kiss et al. (2010) identified several malignancies, such as non-
Hodgkin’s lymphoma (NHL), cervical cancer, and bronchial carcinomas, that were found 
to be increased in SLE patients, with the highest risk occurring in the first year of disease 
diagnosis. Nived, Bengtsson, Jönsen, Sturfel, and Olsson (2001) followed SLE patients to 
determine the rate of new malignancies following initial SLE diagnosis. Parikh-Patel et 
al. (2008) proposed that patients with SLE have an increased risk of developing 
hematologic, kidney, and thyroid cancers. Hildalgo-Conde et al. (2013) suggested that the 
incidence of cancer was four times greater than expected in a cohort study of Spanish 
patients. As shown by the findings from these studies, there is variability in the types of 
cancers that have been found to have an increased incidence in SLE patients.    
Most studies conducted to assess the association of cancer development in 
patients with SLE have been relatively small in size; therefore, the researchers have been 
unable adequately to examine the development and exposures of cancers, especially those 




the multiple factors that play a role in the development of SLE and in cancer. A large, 
population-based database was used to assess the relationship between SLE and cancer in 
a large population. The larger sample size in this study allowed cancers that occur at a 
lower incidence to be examined. Finally, I examined the incidence rates of various cancer 
types found in patients with SLE. The design of the study and the methods to assess the 
findings were dynamic enough to allow for a more detailed analysis that could be easily 
understood.  
Researchers have shown inconsistent relationships between cancer development 
and SLE. The positive associations between hematologic cancers and several 
autoimmune diseases have been demonstrated in several studies. Bernatsky et al. (2008) 
studied immunosuppressive therapy in SLE patients and found that immunosuppressive 
therapy may not be the principle driving factor for overall cancer risk, but may contribute 
to an increased risk of hematological cancers and is likely a plethora of causes that result 
in cancer development in persons with SLE. Kiss et al. (2010) identified that several 
malignancies, such as NHL, cervical cancer, and bronchial carcinomas, are found at a 
higher rate in patients with SLE; in addition, SLE patients have an increased incidence 
and risk of cancer development, with the highest risk occurring in the first year of disease 
diagnosis. Nived et al. (2001) followed SLE patients to determine the rate of new 
malignancies following initial SLE diagnosis. Interestingly, Nived et al. did not find an 
overall increase in the cancer in SLE patients but did find increased frequencies of NHL.  
Although the etiology of autoimmune disorders is not known with certainty, 




attacking itself. Nakazawa (2008) described environmental triggers, such as chemicals, 
drugs, hormones, infections, stress, hormones, behaviors, and diet that are thought to 
cause the body to start producing antibodies against itself. Because a high number of 
autoimmune diseases, such as SLE, are more prevalent in females, hormones may 
contribute to the development of autoimmunity. Approximately 78% to 90% of people 
with SLE are women (Fairweather & Rose, 2004). Because such a high percentage of 
women who develop SLE are women, the activities of hormones, such as estrogen, a 
hormone that has higher levels in women, should be acknowledged in an assessment of 
cancer development in SLE patients. Estrogen is also considered a risk factor for cancers 
such as breast cancer.  
Immunosuppressive therapy is a common treatment for SLE. This therapy is 
implemented to suppress the immunology system and decrease a reaction to the 
production of the antibodies that the body is producing against itself. Bernatsky et al. 
(2008) proposed that immunosuppressive medications used to treat SLE may not be the 
main factor for overall cancer risk in SLE patients. Immunosuppressive medications may 
contribute to an increased risk of developing hematologic cancers, and future scholars 
should evaluate other factors that increase the risk for malignancy in persons with SLE. 
Chang et al. (2005) found that the use of nonsteroidal anti-inflammatory drugs (NSAIDs) 
to treat inflammation increased the risk of NHL. Engels et al. (2005) found Sjögren’s 
syndrome to have the strongest association with immune-related conditions and immune 
modulating medications as risk factors for NHL. Although SLE is different from 




Findings from studies of other autoimmune diseases, such as Sjögren’s syndrome, must 
be considered when studying SLE as in this study because of the similar risk factors and 
treatments. 
There are variable relationships between cancer developments in patients with 
SLE (Bernatsky et al., 2008; Kiss et al., 2010; Parikh-Patel et al., 2008). The smaller 
sample sizes of previous studies have not allowed for an examination of cancers that are 
diagnosed at a lower incidence, which is important because of the various associated risk 
factors, etiology, and pathophysiology of cancers that occur less frequently. There is a 
gap in the current literature on the association between cancer development and SLE, and 
it is not known if there is an increased incidence of cancer development in persons with 
SLE.    
Problem Statement 
Chronic non-communicable diseases (CNCDs), such as SLE, account for a 
significant number of deaths, which are often a result of the impact of SLE on various 
organ systems (Manzi, 2009). However, the increased control of SLE disease activity has 
allowed researchers to study other areas of concern relative to persons with SLE (Manzi, 
2009). In this study, I assessed the association between cancer and SLE.  
Various types of cancer (including NHLs, cervical cancer, and lung cancer) are 
more prevalent in patients with SLE as compared to persons without SLE (Bernatsky et 
al., 2005; Kiss et al., 2010; Parikh-Patel et al., 2008). Researchers have proposed several 
risk factors that may lead to higher rates of cancer in persons with SLE, such as the use of 




al., 2006). Other risk factors that have been suggested, although not fully explored, 
include genetic predisposition such as the presence of antiphospholipid antibodies (which 
are frequently present in persons with both SLE and cancer), lifestyle-related risk factors 
such as smoking, and abnormalities in cell death regulation (Kiss et al., 2010; Tincani et 
al., 2010; Schultz & Harrington, 2003). However, it is uncertain whether SLE is 
associated with a higher rate of cancer (Bernatsky et al., 2005).   
Previous research in assessing cancer development in patients with SLE has been 
based upon small study samples and cohorts that were not closed, which could increase 
the number of patients lost to follow-up. These studies lacked definitive diagnosis dates 
for SLE in the participants (Bernatsky et al., 2005; Parikh-Patel et al., 2008). As a result, 
previous studies were underpowered, and the scholars were unable to determine 
conclusively whether a relationship exists between SLE and cancer (Bernatsky et al., 
2005). Moreover, the smaller sample sizes did not permit those diagnosed at a lower 
incidence to be assessed because there are many risk factors associated with cancer 
development associated with cancers that do not occur at a high frequency. This study 
used a large, population-based database to test the relationship between SLE and cancer. 
The larger sample size in this study allowed cancers that occur at a lower incidence to be 
examined. Finally, I examined the incidence rate of cervical cancer in patients with SLE. 
Purpose of the Study 
A propensity, score-matched, retrospective cohort study among SLE and non-SLE 
female patients identified in the CPRD was used to assess the association between cancer 




included in the study. Non-SLE patients were matched with SLE patients in CPRD. The 
patients were then linked to an additional database for information on covariates. The 
cohort design was most suitable for this study to take advantage of all available data in 
the secondary data sources, to allow multiple outcomes to be examined, causality to be 
assessed, and to allow for the calculation of disease rates in the exposed and unexposed 
patients (Song & Chung, 2010). 
The main exposure was SLE and non-SLE (unexposed), and study patients were 
designated as SLE or non-SLE. Both prevalent and incident cases were included in the 
analysis. The outcome was overall incidence of cancer and incident of cervical cancer. 
Cancer diagnoses were identified in CPRD (Health & Social Care Information Center. 
2014). Incident cases included cases in which cancer was first diagnosed after the index 
date in people with at least 12 months of registration in CPRD. The first diagnosis of 
each cancer type was used in instances where the person had multiple cancer diagnoses at 
different times.  
Data on covariates came from CPRD and HES. Information relating to SLE 
flares, number of hospitalizations, treatment, diagnoses, and medications came from 
HES. Each SLE patient was matched to non-SLE patients using variables to determine 
the probability of developing SLE (p [SLE]) in the patients. Balance between the exposed 
(SLE) and non-exposed (non-SLE) cohorts was obtained by using variables that were 
associated with the development of SLE to determine the treatment and non-treatment 




in the cohorts. The control of the number and similarity of variables in the patients in 
each cohort kept the variables balanced between the study participants.  
Research Questions and Hypotheses 
RQ1: Is the risk of cancer development increased in SLE patients compared to non-SLE 
patients? 
H01: There is no increased risk of cancer development in SLE patients compared to non-
 SLE patients for overall cancer risk and cervical cancer risk. 
Ha1: There is an increased risk of cancer development in SLE patients compared to non-
 SLE patients for overall cancer risk and cervical cancer risk. 
Theoretical Framework 
The disease causation theory was the conceptual framework for this study. In this 
study, I assessed the association between cancer and SLE as compared to rates of cancer 
in non-SLE patients. There are many challenges in determining associations, especially in 
chronic diseases such as SLE and cancer. These two diseases involve multiple factors that 
interact and result in their disease state. The complexity of these two CNCDs led to the 
selection of a multifactorial causation theory as the basis for this study. The basic 
components of the multifactorial framework are that diseases have many causes, which 
cannot be independently attributed as the sole causative agent (Broadbent, 2009). The 
multifactorial framework was relevant for this study because of the multiple agents that 
have been proposed to cause SLE and to cause cancer, and because disease activity in 




The disease causation theory has been used to explain CNCDs such as diabetes, 
cancers, and autoimmune diseases (Najman, 1980). Unlike communicable diseases that 
can be attributed to a microorganism, these diseases do not originate from an organism, 
nor are they transmitted communicably. These factors of origination and method of 
transmission disqualify these diseases from being explained by the mono-causal model of 
disease that was applicable to communicable infectious diseases prevalent in the 19th 
century (Najman, 1980). Whereas diseases, such as smallpox, could be traced to a 
causative organism, diseases such as SLE and cancer cannot be traced to a single 
causative organism; these diseases are proposed to be caused by multiple factors such as 
environment, genetics, lifestyle choices, and possible organisms that result in the disease 
state (Broadbent, 2009). These multiple factors may explain the development of these 
diseases although no single factor by itself leads to the development of cancer or 
autoimmune diseases. The multifactorial disease causation theory was used as the 
foundation of this study because both SLE and cancers are the result of the occurrence of 
multiple factors. 
Nature of the Study 
A matched, retrospective, cohort study among SLE and non-SLE patients 
identified in the CPRD was used to assess the association of cancer development in 
patients with SLE. SLE patients with prevalent and/or incident cases were included in the 
study. Non-SLE patients were matched with SLE patients (4 to 1) on age, gender, 
practice, and date of registration in the CPRD. The patients were linked to the death 




Table 1). The cohort design is most suitable for this study to take advantage of all 
available data in the secondary data sources, the CPRD, and the death registry. The 
cohort design allowed for multiple outcomes to be examined, causality to be assessed, 
and rare cancer exposures to be investigated. This design allowed for the calculation of 
disease rates in the exposed and unexposed patients (Song & Chung, 2010). 
Table 1 
Definitions 
Variable Definition How Measured 
Age  
(independent) 









Medications that cause the 





Diagnosis of SLE as per 
American College of 
Rheumatology (ACR) or No 
diagnosis of SLE has been 
made 
Categorical 
(Severe or Mild) 
Cancer Development 
(dependent) 
Diagnosis of a cancer Categorical 
 
The methodology used was quantitative, and the design was a high-dimensional 
propensity model. The main exposure was SLE (exposed), and study patients who did not 
have SLE were designated as SLE or non-SLE. Both prevalent and incident cases were 
included in the analysis. The outcome was cancer overall and cervical cancer in 
particular. Malignant cancer diagnoses were identified in CPRD, HES, and the death 




was first diagnosed after the index date in people with at least 12 months of registration 
in CPRD. The first diagnosis of each cancer type was used in instances where the person 
had multiple cancer diagnoses at different times.  
Disease severity was measured by the use of IC treatment, along with other 
treatments such as NSAID and antimalarial drugs, which can be a proxy for disease 
activity and was considered a time dependent variable. A level of disease severity (e.g., 
mild, severe) was assigned based upon the number of comorbidities, number of 
hospitalizations, severe complications (e.g., renal transplantation), and use of IC 
treatments. The definition of this variable depended on what was available in the 
database.   
Assumptions 
Assumptions critical to the meaningfulness of this study that could not be 
demonstrated to be true included that data entered into the CPRD were accurate. The 
CPRD has been noted as having a high rate of data entry by the practitioners and was 
used in several studies for this reason. It was also assumed that patients diagnosed with 
SLE were accurately diagnosed, and the non-SLE patient did not have SLE.   
Scope and Delimitations 
An increase in life expectancy for persons with SLE has resulted in the 
recognition of other chronic diseases as cause for death in patients with SLE. Previous 
studies of cancer development in SLE patients have speculated that medications 
commonly used to treat SLE may be contributing factors. This study assessed whether the 




I chose to focus on overall cancer development and cervical cancer in particular. The 
cohorts consist of women only, which is the reason that cervical cancer was focused upon 
in this study. I specifically chose to not focus on cancers that have a higher incidence in 
the male population because only women will be included in this study. By focusing on 
overall cancer development and cervical cancer development in women, the findings are 
generalizable to women with SLE. 
Limitations 
The validity of this study depended on the accuracy and reliability of the 
information entered into the database. SLE is a difficult diagnosis to make, and there may 
have been a risk of including non-SLE patients. I excluded cases that were diagnosed 
within 6 months because both SLE and some cancers may have similar symptoms, and it 
may not be clear which diagnosis preceded the other. This scenario may threaten the 
validity of the study by possibly including patients who were inaccurately diagnosed with 
SLE or who had not been diagnosed with SLE when they should have been.  
In a clinical study, bias refers to any errors in the study (Gerhard, 2008). The 
identification of bias or potential bias in a study allows the researcher to include steps 
that can assist in counteracting areas of bias. The most common areas of bias occurred in 
the history of the patients admitted into the study, the inclusion criterion used to select 
patients into the study, and the methods used to analyze the study results (Gerhard, 2008).  
The study population included females with SLE and matched female non-SLE 
patients. Patients with a diagnosis of SLE were matched to non-SLE females using 




patients by using risk factors associated with SLE was one method to address bias that 
can enter a study by using the history of the patients in the comparison groups. Risk 
factors associated with the development of SLE were used to select the participants in 
both comparison groups. This matching decreased bias due to the selection process. A 
lack of consideration of the history of the patients, especially those factors that could lead 
to the development of SLE, could create bias between the comparison groups. The 
propensity score method of matching also addressed bias that is commonly a result of 
inclusion and exclusion criterion for a study. Selection using propensity score matching 
ensured that the comparison groups were equal in their covariates that could lead to the 
development of SLE and cancer.  
Limitations are inevitable in research. CPRD is a combined effort of the MHRA’s 
General Practice Research Database (GPRD) and the Department of Health’s NIHR 
Research Capability Program (RCP) into a secure electronic research database. The use 
of data that have already been collected has limitations in that the research questions must 
be tailored around the information that is available in the database. An additional 
limitation associated with using CPRD is that I am not sure if the data were entered into 
the database with accuracy and reliability. CPRD does have the ability to be linked to 
other major databases such as the United Kingdom and Ireland Association of Cancer 
Registries (UKIACR) at a cost. The lack of funds to have CPRD linked with the 
UKIACR created another limitation in that the source of the most comprehensive data on 
cancer was not used in the study. The HES database was used because the UKIACR 





Better control of SLE flares has resulted in fewer deaths caused by disease 
activity in this population of patients. Chronic diseases such as cancers have now been 
shown to be causes of death in patients with SLE. Current cancer screening 
recommendations for SLE patients may not be enforced enough to encourage patients to 
adhere to them. It is necessary to understand the association of cancer development in 
patients with SLE to create positive social change, which will support adherence of 
cancer screening recommendations.  
Previous studies on the association of cancer development in patients with SLE 
have shown variable outcomes. Because several of the previous studies have been small 
and the comparison groups did not seem to be balanced as far as exposure to risk factors 
associated with SLE and cancer development, this study included a large population and 
balanced the cohorts based upon risk factors of SLE and cancer. The larger size of this 
study resulted in results that are generalizable. The study design, a high dimensional 
propensity model, allowed the patients to be balanced based on their exposure to 
medications and other diseases. This balance is significant because of the many factors 
that have been found in previous studies to contribute to chronic diseases such as cancer.   
Summary 
As discussed in this chapter, persons diagnosed with SLE are being diagnosed 
earlier, which has resulted in the use of medications that decrease the devastation cause to 
body organs because of flares. These factors have resulted in persons with SLE living 




find that patients with SLE are now having chronic diseases such as cancer to cause 
mortality in SLE patients. Several studies have been conducted to assess the association 
of cancer development in patients with SLE, but many of the studies had a small study 
population and the results have had variability in the findings. My study used a large 
population-based database, the CPRD, to assess that association of cancer development in 
SLE patients. The large study population and the use of a high dimensional propensity 
model to select the cohorts resulted in cohorts that were balanced in terms of medications 
used and concurrent diagnoses experienced in patients in each of the cohorts. The balance 
of the cohorts in this study, because of the use of a high dimensional propensity model, 
allowed an equitable assessment of cancer development in patients with SLE.  
In Chapter 2, a synopsis of the current literature on the problem will be presented 
with the strategy used to research the literature and a literature review of key elements 
related to concepts, variables, and methodology. A description of how the present study 
fills the gaps in the literature and how the results of this study will extend knowledge in 





Chapter 2: Literature Review 
Introduction 
CNCDs such as SLE account for a significant number of deaths (Manzi, 2009). 
Persons with SLE are 2.4 times more likely to die of any cause than a non- SLE person 
after adjusting for demographic characteristics (Bernatsky, 2006). SLE is difficult to 
diagnose because it involves multiple organ systems, and it has no single diagnostic 
marker; rather, several different clinical symptoms and laboratory values must be 
combined eventually to diagnose the disease (Gill, Quisel, Rocca, & Walters, 2003). 
Diagnosis of SLE is made after the patient has exhibited 4 of 11 clinical symptoms and/or 
laboratory criteria. The average person with an autoimmune disease has a lifespan 
shortened by 15 years, and autoimmune diseases are the eighth leading cause of death 
among females (Nakazawa, 2008). The difficulty is diagnosing SLE and the impact of the 
lifespan has a significant economic impact of the public health system. 
As previously stated, the economic burden caused by autoimmune diseases makes 
them a public health concern. The health care burden is estimated at approximately $120 
billion, compared to $70 billion for cancer (Nakazawa, 2008). Additional burdens are 
placed on the health care system because of multiple trips to health care professionals in 
an attempt get an accurate diagnosis. In addition, patients with autoimmune diseases 
often face a poor quality of life that includes physical changes in their appearance (i.e., 
hair loss, facial rashes, loss of job, and/or eventual disability status) (Bertsia, Cervera, & 
Boumpas, 2012). The control of SLE flares has decreased the damage on organ systems 




control of SLE disease activity has now allowed researchers to study other areas of 
concern relative to persons with SLE (Manzi, 2009). In this study, I assessed the 
association of malignancies in persons with SLE. 
Various types of cancer, including NHLs, cervical cancer, and lung cancer, 
increase in patients with SLE as compared to persons without SLE (Bernatsky et al., 
2005; Kiss et al., 2010; Parikh-Patel et al., 2008). Interestingly, people with SLE were 
also found to be less likely to die of cancer (except for NHL and lung cancer) as 
compared to non-SLE persons (Bernatsky et al., 2006). Persons with SLE had a SMR of 
2.8 for NHL and a SMR of 2.3 for lung cancer (Bernatsky et al., 2006).  
Researchers have proposed several risk factors for the development of cancer 
among persons with SLE that would support an increased risk of cancer in this 
population, including the use of immunosuppressive agents, which increases the 
development of malignancies (Bernatsky et al., 2006). Other risk factors that have been 
suggested, although not fully explored, include genetic predisposition such as the 
presence of anti-phospholipid antibodies, which are frequently present in persons with 
both SLE and cancer; lifestyle-related risk factors such as smoking; and abnormalities in 
cell death regulation (Kiss et al., 2010; Schultz & Harrington, 2003; Tincani et al., 2010). 
However, whether or not SLE is associated with a higher rate of cancer is uncertain 
(Bernatsky et al., 2005). Previous research in this area has been based upon small study 
samples and cohorts that were not closed, which could increase the number of patients 
lost to follow-up, and the studies have lacked definitive diagnosis dates for SLE in the 




studies were generally underpowered to determine conclusively whether a relationship 
exists between SLE and cancer (Bernatsky et al., 2005). Moreover, the smaller sample 
sizes did not permit an examination of cancers that are diagnosed at a lower incidence, 
which is important because of the various associated risk factors, etiology, and 
pathophysiology of cancers that occur less frequently. This study used a large, 
population-based database to test the relationship between SLE and cancer in a large 
population. The larger sample size in this study allowed cancers that occur at a lower 
incidence to be examined. Finally, this study examined the incidence rates of various 
cancer types found in patients with SLE. 
In this chapter, a discussion of literature on the pathogenesis of SLE and of cancer 
will be reviewed, followed by highlights of etiological similarities between the two 
chronic diseases. In addition, other autoimmune diseases that have established 
associations to specific cancers will be highlighted. I will then provide a review of 
literature written and based upon completed studies on the association between cancer 
and SLE with a focus on the types of cancers that have been found to have an increase in 
incidence in those studies. Finally, a review of literature on the medications used to treat 
SLE will be discussed.   
Literature Search Strategy 
The literature review should consist of studies that are similar to the research 
topic (Creswell, 2009). The literature contained in this review was used to establish a 
relationship with my study to research that has already been conducted. The principle 




Library. The MedImmune Corporate Library allows access to multiple electronic 
resources such as e-journals (greater than 12,000), online books (greater than 7,000), and 
dozens of databases such as Biosis, Embase, Medline/PubMed, SciFinder, Scopus, and 
Web of Science. The Walden University Library EBSCO databases were also used for 
literature searches. Other databases that were accessed included the Cumulative Index to 
Nursing & Allied Health Literature (CINAHL), MEDLINE, and ProQuest. Governmental 
Web sites, such as the U.S. Centers for Disease Control and Prevention (CDC) and the 
Medicines and Healthcare Products Regulatory Agencies (MHRA), were also used.  
Strategies used when searching for and identifying articles for this literature 
review included the use of key words to search for articles (see Table 2). Key words and 
word combinations used to conduct searches included systemic lupus erythematosus, 
autoimmune diseases, cancer and autoimmune diseases, malignancies, cancer 
development, and autoimmunity. Once I found the articles, I reviewed the abstracts and 
read through the articles to determine if they would make a contribution to my 
understanding of the research topic. I also used guides to terms to locate articles 
(Creswell, 2009). Using multiple resources and databases allowed me to find several 







Search Terms and Combinations for Literature 
Topic(s) Key words Combinations 
Theory theories chronic disease theories 
  causation theory 
SLE etiology systemic lupus lupus & autoimmunity  
 erythematosus lupus pathogenesis 
 SLE  
 Lupus  
cancer etiology cancer cancer pathogenesis 
  malignancy  
 lymphomas  
common links  cancer & SLE 
incidence of cancer  lupus & cancer 
cancer development  lymphomas in lupus 
  auto antibodies in cancer 
and lupus 
drugs and cancer lupus treatments cancer in lupus 
 
Articles published within 10 years of data collection were included in the study, 
unless there was limited information or published research on the topic or the research 
had a significant impact on the scientific body of knowledge of cancer or autoimmunity. I 
retrieved approximately 200 articles of which approximately 100 were found to be related 
to my study. Several articles were eliminated because the date of publication was greater 
than 10 years. Other articles were eliminated because the results appeared to be biased, or 
the journals were not peer-reviewed. 
Theoretical Foundation 
Because both SLE and cancer have a plethora of proposed causes, the disease 




proposes that diseases have many causes, which cannot be independently attributed as a 
sole causative agent (Broadbent, 2009). This multifactorial framework served as a basis 
to assess the use of immunosuppressive therapies and cancer development in persons 
with SLE. This framework also served to assess the development of specific types of 
cancers, such as cervical cancer and lung cancer in persons with SLE.  
The disease causation theory was used to build the conceptual framework for this 
study. This study assessed the association of malignancy in patients with SLE. There are 
many challenges in determining associations especially in chronic diseases such as cancer 
and SLE. These two diseases involve multiple factors that interact and result in their 
disease state. The complexity of these two CNCDs resulted in the selection of a 
multifactorial causation theory as the basis of this study. The basic components of the 
multifactorial framework are that diseases have many causes, which cannot be 
independently attributed as the sole causative agent (Broadbent, 2009). The multifactorial 
framework was most relevant for this study because of the use of immune compromising 
treatments for SLE treatment and disease activity in SLE can both contribute to increased 
risk of cancer development.  
The disease causation theory has been applied to explain CNCDs such as 
diabetes, cancers, and autoimmune diseases. Unlike communicable diseases that can be 
attributed to a specific microorganism, these diseases do not originate from an organism, 
nor are they transmitted communicably. These factors of origination and method of 
transmission disqualify these diseases from being explained by the mono-causal model of 




prevalent in the nineteenth century. Whereas diseases such as smallpox could be traced to 
a causative organism, diseases such as SLE and cancer cannot be traced to a single 
causative organism, but are proposed to be caused by multiple factors such as 
environment, genetics, lifestyle choices, and possible organisms that result in the disease 
state. These multiple factors together may explain the development of these diseases 
although no single factor by itself leads to the development of cancer or several of the 
autoimmune diseases. The multifactorial disease causation theory was used as the 
foundation of this study because both SLE and cancers are the result of the occurrence of 
multiple factors. 
Etiology of SLE 
SLE is a chronic inflammatory autoimmune disorder that occurs when the body’s 
immune system attacks its own tissues and organs. An overactive immune response by 
the body against substances and tissues that are in the body, along with an inability to 
tolerate self-antigens, characterize the development of autoimmune diseases (Cristaldi, 
Malaguarnera, Rando, & Malaguarnera, 2011). Nagy, Koncz, and Perl (2005) described 
the etiology of SLE as a decrease in tolerance to self-antigens with polyclonal activation 
of B lymphocytes, production of different autoantibodies, and alteration in the function of 
T cells. This alteration in the T cells impacts T cell homeostasis and the modulation of 
immune responses to allergens, cancer cells, and pathogens (Belkaid, Piccirillo, Mendez, 
Shevach, & Sacks, 2002). SLE could be summarized as an immune response against 
internal nuclear antigens, which have been released from cells that were programmed to 




these cells results in the production of helping B cells, which produce autoantibodies and 
secrete cytokines (regulatory proteins) that interact with cells of the immune system to 
mediate the immune response (Bertsias et al., 2012). 
Etiology of Cancer 
Cancer is a broad term that describes more than 100 diseases in which cell 
division gets out of control and invades other tissues in the body by spreading via the 
blood and/or lymphatic systems (National Cancer Institute [NCI], 2014). The body is 
composed of cells that grow, divide, and die; they are then replaced with new cells. 
However, cancer occurs when the cells genetic material gets damaged and the cells stop 
the normal cycle of dying, and their growth gets out of control (NCI, 2014). Damaged 
genetic materials of cells produce mutations, which affect normal cell growth (Bertsias et 
al., 2012). Cancers can either spread to other areas of the body (metastatic), or it can be 
contained in just one area of the body (benign). In 1999, cancer replaced heart disease as 
the leading cause of death among men and women 85 years of age and younger (Siegel, 
Ward, Brawley, & Jemal, 2011). 
Many cancers have been associated with activities, elements in the environment, 
medications, and with disease processes. Age increases the likelihood of developing 
some types of cancer because of the longer exposure to potential carcinogens in the 
environment, foods, and other factors (Extermann, 2000). The risk of developing certain 
cancers in patients with rheumatic disease varies and has been found to have a higher 
prevalence depending upon the rheumatic disease (see Table 3). Several drugs and 




development (Extermann, 2000). (Drugs used to treat autoimmune diseases will be 
discussed in depth later in this paper.)  
Table 3 
Rheumatic Diseases and Associated Malignancies 
Rheumatic Disease Organs Primarily 
Impacted by the 
Rheumatic Disease 
Most Common 




Joints Lymphomas Blood & lymph 
Primary Sjögren’s 
Disease 
Mucous membranes Lymphomas Blood & lymph 
Primary 
Scleroderma 
Integumentary Alveolar cell 
carcinoma 
Respiratory 
  Non-melanoma skin 
cancer 
Integumentary 
  Adenocarcinoma of 
the esophagus 
Gastrointestinal (GI) 
SLE Various Lymphomas Blood & lymph 









Turesson and Matteson (2013) noted that persons with rheumatoid arthritis have 
been found to have an increased risk of developing lymphomas, which are cancers that 
originate in the immune system and more specifically the lymphatic system. This finding 
is significant because several research studies have found HL and NHL to be elevated in 
patients with SLE. Both of the cancers originate in the immune system and more 




Malignant lymphomas are classified according to the cell of origin and the 
biological understanding of the cell type; they have been indexed by the World Health 
Organization (WHO) (Word & Matasar, 2012). The malignant lymphomas are 
heterogeneous and originate from either B cells or T cells (Word & Matasar, 2012). B 
lymphocytes (B cells) fight against viruses and bacteria by producing proteins called 
antibodies, which attach to the germ so that other cells in the immune system know that 
they need to destroy them (American College of Rheumatology [ACR], 2013). T cells 
either destroy the marked germs, or they release other substances, which will digest the 
marked germs (ACR, 2013). The WHO has classified more than 50 types of lymphomas. 
However, I focused primarily on two types: non-Hodgkin’s (NHL) and Hodgkin’s 
lymphomas (HL). In 2011, approximately 66, 360 cases of NHL cases and approximately 
8,830 cases of HL cases were diagnosed (Siegel et al., 2011). Previous studies have 
shown that NHLs and HLs have both been elevated in patients with SLE. 
HL results from the malignant transformation of a B cell at either the post-
germinal or post-germinal center stage of development (Word & Matasar, 2012). Of the 
8,830 cases of HL diagnosed in 2011, approximately 1,300 resulted in death (Siegel et 
al., 2011). Diagnosis is more prominent in patients aged 20 to 29 years or greater than 
age 50 years; in addition, HL has a higher incidence in males than in females (Word & 
Matasar, 2012). In approximately 40% of HL cases, Epstein-Barr virus is detectable, and 
it is thought to be directly involved in the transformation to cancerous cells (Word & 




also been a possible precursor in the transformation of the body producing antibodies 
against itself as in autoimmune diseases.  
NHL also starts in the lymphocytes. There are several subtypes of NHLs but I 
primarily focused on the diffuse large B cell lymphoma (DLBCL). Mucosa-associated 
lymphoid tissue (MALT) type NHLs are often found following an autoimmune or 
chronic infectious process (Word & Matasar, 2012). The pathophysiology involves 
chronic stimulation of B lymphocytes by a persistent infection or autoimmune 
phenomenon that results in the cells cloning themselves (Word & Matasar, 2012). The 
DLBCL may occur as a transformation of a previously existing slow lymphoma that may 
or may not have been previously diagnosed (Word & Matasar, 2012). A weakened 
immune system and certain types of infections contribute to the development of NHLs. 
Certain infections have also been attributed to the production of autoantibodies, which act 
against the body, as in autoimmune diseases.  
A greater incidence of lymphoproliferative cancers in autoimmune diseases 
should be expected because the chronic activation of B cells and T cells that occur in 
autoimmune diseases could serve as a catalyst to cancer development (Turesson & 
Matteson, 2013). Ragnarsson, Grondal, and Steinsson (2003) determined that patients 
with SLE are at increased risk for cancer development; surprisingly, prostate cancer was 
found to be increased in men with SLE. There was speculation that the increased prostate 
cancer rate could be possibly attributed to etiological mechanisms in males with an 




which result in a decrease in the protective effect of estrogen for prostate cancer 
(Ragnarsson et al., 2003).  
Common Links between Cancers and Systemic Lupus Erythematosus 
Researchers have proposed several risk factors for the development of cancer 
among persons with SLE that would support an increased risk of cancer in this 
population, including the use of immunosuppressive agents, which increases the 
development of malignancies (Bernatsky et al., 2006). Other risk factors that have been 
suggested, although not fully explored, include genetic predisposition such as the 
presence of anti-phospholipid antibodies, which are frequently present in persons with 
both SLE and cancer; lifestyle-related risk factors such as smoking; and abnormalities in 
cell death regulation (Kiss et al., 2010; Schultz & Harrington, 2003; Tincani et al., 2009). 
Both SLE and cancers are the result of cells in the body behaving in a manner that 
was not intended. These abnormal cell activities have some commonality in that (a) they 
have patterns of dysregulation that are similar such as autoantibodies in the blood; (b) 
they have bidirectional linkages as evidenced by clinical manifestations; and (c) 
immunosuppressive drugs used to treat these diseases can have an impact in cancer 
development (Achenza & Selmi, 2012). All cancers originate in cells of the body, which 
are the basic units of life (NCI, 2014). The fact that both cancers and autoimmune 
diseases originate at the cellular level is a primary link that may be instrumental in 
understanding whether the two disorders have an association with each other. The 




greater propensity for lymphomas to be found in persons with autoimmune diseases 
(Cristaldi et al., 2011).    
Abu-Shakra, Ehrenfeld, and Shoenfeld (2002) proposed that both autoimmune 
diseases and cancers have common etiologic agents such as environmental factors, the 
use of immunosuppressive agents, genetic factors that render them susceptible, and 
disturbances in the immune system. In the case of cancer and autoimmune diseases, it is 
difficult to determine which began first and whether the advent of one created a suitable 
environment for the other to begin. In addition, whether the use of treatment drugs caused 
the development of either lymphoma or an autoimmune disease is also questionable. 
These are the major issues faced when assessing the association of cancer in autoimmune 
diseases. Because of the heterogeneity of both cancers and autoimmune disorders, a 
causal relationship can be difficult to determine with certainty. Rosenquist (2008) found 
associations between inflammation, infectious agents, and certain lymphomas. The 
genetic make-up of individuals plays a role in the development of SLE and cancer as 
does the diet; the air quality; exposure to drugs, other than ones used for treatment for 
one of the disorders; and habits, such as smoking and tanning, which significantly impact 
the association. These are just a few of the numerous factors that may affect the 
association of cancer and SLE. These factors can cause a great impact on an association 
between cancer and autoimmune diseases.  
Bei et al. (2009) studied the interaction between autoantibodies in cancer patients 
versus autoimmune patients. The authors found an overlap of antibodies that must be 




growth and progression of each disease. Most studies conducted to date have been 
relatively small in size and unable adequately to examine the development and exposures 
of cancers that are not common. Outcomes from this study revealed that there is an 
association of cancer development in patients with SLE. More specific association of 
cervical cancers was also assessed in this study. The study outcomes could promote 
positive social change by reinforcing current recommendations for cancer screenings 
particularly in persons with SLE. Stronger adherence to cancer screening 
recommendations could enhance the ability to detect a cancer early enough so that 
treatment can be implemented that may result in a higher likelihood to effectively 
eradicate the cancer and decrease mortality due to cancer in persons with SLE. Results 
from this study may also equip persons with SLE with scientifically-based knowledge 
that will enable them to make decisions regarding their care with a clearer understanding 
of the cancer risks inherent to persons with SLE, particularly when factored with their 
knowledge of their personal familial risks for cancer development.  
Incidence of Cancer in Autoimmune Diseases 
Various types of cancer, including but not limited to cervical cancer and lung 
cancer, are thought to be increased in patients with SLE when compared to persons 
without SLE (Bernatsky et al., 2005; Kiss et al., 2010; Parikh-Patel et al., 2008). 
Researchers have proposed several risk factors for the development of cancer among 
persons with SLE that would support an increased risk of cancer in this population, 
including the use of immunosuppressive agents, which increase the development of 




although not fully explored, include genetic predisposition such as the presence of anti-
phospholipid antibodies, which are frequently present in persons with both SLE and 
cancer, lifestyle-related risk factors such as smoking, and abnormalities in cell death 
regulation (Kiss et al., 2010; Schultz & Harrington, 2003; Tincani et al., 2010).  
Whether SLE is associated with a higher rate of cancer is uncertain (Bernatsky et 
al., 2005). Previous research in this area has been based upon small study samples, 
cohorts that were not closed, which could increase the number of patients lost to follow-
up; moreover, the studies have lacked definitive diagnosis dates for SLE in the 
participants (Bernatsky et al., 2005; Parikh-Patel et al., 2008). As a result, previous 
studies were generally underpowered to determine conclusively whether a relationship 
exists between SLE and cancer (Bernatsky et al., 2005). The smaller sample sizes did not 
permit an examination of cancers that are diagnosed at a lower incidence, which is 
important because of the various associated risk factors, etiology, and pathophysiology of 
cancers that occur less frequently.   
Cancer Development and Systemic Lupus Erythematosus Disease 
Studies completed to date have shown variable relationships between cancer 
developments in persons with SLE. The positive associations between hematologic 
cancers and several autoimmune diseases have been repeatedly demonstrated in several 
studies to date. Bernatsky et al. (2008) studied immunosuppressive therapy in SLE 
patients and found that immunosuppressive therapy may not be the principle driving 
factor for overall cancer risk, but may contribute to an increased risk of hematological 




patients. Broadbent (2009), in an examination of disease causation models, confirmed 
that a thorough understanding of the effects of various factors that contribute to a disease 
is necessary to measure an association of the variable to disease development. Kiss et al. 
(2010) identified several malignancies such as NHL, cervical cancer, and bronchial 
carcinomas, which are found in patients with SLE, are increased, and SLE patients have 
an increased incidence and risk of cancer development with the highest risk occurring in 
the first year of disease diagnosis. Nived et al. (2001) followed SLE patients to determine 
the rate of new malignancies following initial SLE diagnosis. Parikh-Patel et al. (2008) 
determined that patients with SLE have an increased risk of developing hematologic, 
kidney, and thyroid cancers. Hildalgo-Conde et al. (2013) actually suggested the 
incidence of cancer was four times greater than expected in a cohort study of Spanish 
patients.     
Systemic Lupus Erythematosus Treatment Drugs and Cancer Development 
Over the years, many drug classes have been found to be carcinogenic (Azab et 
al., 2008). Unlike many autoimmune diseases, SLE has only recently had a drug 
approved for the treatment of the disease. Until belimumab (Benlysta™) was approved 
for the treatment of SLE, other drugs were used as off-label treatments. The standard of 
care for SLE includes anti-inflammatory drugs, corticosteroids, antimalarial drugs, 
immunosuppressive drugs, and anticoagulants (Azab et al., 2008). Anti-inflammatory 
drugs, such as aspirin, acetaminophen, and non-steroidal anti-inflammatory drugs 
(NSAIDs) such as ibuprofen, are used to decrease inflammation. Corticosteroids are used 




Antimalarial drugs are used for skin rashes. Immunosuppressive drugs are used to control 
inflammation when corticosteroid drugs have not effectively controlled the inflammation. 
Anticoagulants are used in SLE patients to prevent blood clots that can result from 
decreased mobility in people with SLE.  
Bernatsky et al. (2008) proposed that immunosuppressive medications used to 
treat SLE may not be the main factor for overall cancer risk in SLE patients. 
Immunosuppressive medications may contribute to an increased risk of developing 
hematologic cancers, and suggests that future studies should evaluate other factors that 
increase the risk for malignancy in patients with SLE. Chang et al. (2005) found that use 
of NSAIDs to treat inflammation increased the risk of NHL. A study by Engels et al. 
(2005) found Sjögren’s syndrome to have the strongest association in a study to assess 
immune-related conditions and immune-modulating medications as risk factors for NHL.  
The theoretical framework for this study was the disease causation theory. The 
basic component of the disease causation theory is that diseases are caused by multiple 
factors and cannot be independently attributed to a sole causative agent (Broadbent, 
2009). The multifactor framework was most useful because of the use of immune-
compromising treatments for SLE treatment and disease activity in SLE, both of which 
could possibly contribute to increased risk of cancer development. Determining the cause 
for CNCDs is challenging because they involve multiple factors that interact and result in 
the disease state. This study involved two CNCDs, SLE, and cancers. Complexities of 




Summary and Conclusions 
Studies completed to date have shown variable relationships between cancer 
developments in persons with SLE. The smaller sample sizes of previous studies have not 
allowed an examination of cancers that are diagnosed at a lower incidence, which is 
important because of the various associated risk factors, etiology, and pathophysiology of 
cancers that occur less frequently. There is a gap in the current literature available on the 
association of cancer development in SLE patients, and it is not definitively know if there 
is an increased incidence of cancer development in SLE patients.    
In this study, careful consideration was given to the multiple factors that have an 
interaction in SLE and in cancer. A large, population-based database was used to assess 
the relationship between SLE and cancer in a large population. The larger sample size in 
this study allowed cancers that occur less frequently to be examined. Finally, this study 
examined the incidence rates of various cancer types found in patients with SLE. The 
design of the study and the methods used to assess the findings were dynamic enough to 
allow for a detailed analysis that can be easily understood. The next chapter will provide 
details of the research design and methodology that was used in this study. A discussion 





Chapter 3: Research Method 
Introduction 
In Chapter 2, I presented the results of several research studies on the possible 
risk factors for the development of cancer among persons with SLE. They included the 
use of immunosuppressive agents, genetic predisposition (presence of antiphospholipid 
antibodies), lifestyle-related risk factors such as smoking, and abnormalities in cell death 
regulation (Bernatsky et al., 2006; Kiss et al., 2010; Schultz & Harrington, 2003; Tincani 
et al., 2010). However, whether SLE is associated with a higher rate of cancer is 
uncertain. A notable limitation with the existing research in this area (small study 
samples, low retention rates, and a lack of a definitive and consistent diagnosis of SLE in 
the study participants) renders uncertainty about the ability to apply rates found to the 
general population (Bernatsky et al., 2005; Parikh-Patel et al., 2008). Moreover, the small 
sample sizes of several of the studies presented in the previous chapter prohibit an 
examination of cancers that are diagnosed less frequently. Less frequently diagnosed 
cancers are important because of the various associated risk factors, etiology, and 
pathophysiology of tumors that may occur less frequently.   
This study was designed to address the limitations of previous research. I used a 
population-based database (CPRD) with a large sample size, which permitted an 
examination of cancers that occur at a lower incidence. Follow-up was not problematic 
because all data had already been collected and archived in the respective database. SLE 
was defined as any patient who had been diagnosed with SLE as per the American 




In this chapter, the study design will be described along with the justification for 
the use of the analytical approach including its advantages over other models and 
limitations. A description of the target population will also be presented. The calculation 
of the minimum sample size needed to show an adequate statistical power to detect a 
treatment effect will be provided, along with the parameters and assumptions used to 
perform this computation. Finally, the procedure for gaining access to data archived in 
the CPRD will be described along with a description of anticipated threats to validity and 
potential ethical issues that were encountered during the study. 
Research Design and Rationale 
A matched, retrospective, cohort study among SLE and non-SLE patients 
identified in the CPRD was conducted to assess the association of cancer development in 
patients with SLE. SLE patients, including both prevalent and incident cases, were used 
in the study. Incident cases were defined as those with the first diagnosis of SLE after the 
last date of current registration (CRD) and the practice up-to-standard (UTS) date plus 12 
months. The CRD was the date that the patient’s information was entered into the CPRD; 
whereas, the practice UTS date was the date that the CPRD staff confirmed that the data 
met their internal quality standards. Prevalent cases were defined as those that had the 
first SLE diagnosis prior to the later of the CRD date and the UTS date plus 12 months. 
The index date for incident cases was the date of SLE diagnosis. The index date for the 
prevalent cases was the later of the CRD date and UTS date plus 12 months. The 
comparison group was a non-SLE cohort selected from CPRD. Non-SLE patients must 




cohort. This exclusion criterion prevented patients who experienced drug-induced lupus 
erythematosus (DILE) from entering the study. DILE can result after taking certain drugs 
and usually resolves on its own. Because DILE has a different pathophysiology than 
SLE, it was not included in this study.  
Randomization that occurs in a randomized controlled trial (RCT) theoretically 
ensures a balance of measured and unmeasured covariates amongst the experimental and 
the control groups (Austin, 2011). However, in an observational study, the patients are 
assigned to a group, but the groups will differ in systematic ways. This method of group 
assignment did not take into consideration the fact that patients in either group may have 
had concurrent diseases, may have been undergoing treatments, and may have possessed 
other characteristics that could interfere with an equitable evaluation of the outcome 
(Sugihara, 2010). Group assignment without a method to control for confounding 
characteristics introduces selection bias for the study because the study results were not 
generalizable because of the numerous confounding variables for both cancer and SLE. 
Studies of association of cancer development in patients with SLE have not used a 
propensity score methodology until this study. The study design allows the cohorts to be 
balanced better than previous studies that have assessed cancer development in patients 
with SLE. Sugihara (2010) recommended the use of propensity score methodology in 
observational studies in which multiple confounding characteristics are present in the 
patients. This method helps to balance the differences between comparison groups. The 
propensity score is the predicted probability given a determined set of measured 




score allows an observational (nonrandomized) study to be designed and analyzed, so 
that it mimics many of the characteristics of an RCT (Austin, 2011). This method is 
based upon the creation of a similar distribution of observed baseline covariates between 
the two groups, and it was used in this study to help to balance the measured differences 
between the comparison groups.  
The propensity score analysis in this study began by identifying risk factors for 
SLE. A logistic regression model was used to determine the risk of developing SLE. The 
predicted probability of developing SLE p(SLE) was going to be calculated by the 
regression of the covariates on a dichotomous variable for whether a patient has SLE. 
This calculation would have produced a probability of SLE for each woman in the cohort. 
Patients with and without SLE would have be matched based on the p(SLE) (Caliendo & 
Kopeinig, 2005). This matching could only occur within the area of common support, 
which is the range of p(SLE) that is common to both the SLE and non-SLE women, so it 
would exclude women with very high and low probability of having SLE.   
Once the risk factors that contribute to the development of SLE were determined, 
a test to check if the matching procedure balanced the distribution of the relevant 
variables in the control and treatment groups would have been performed (Caliendo & 
Kopeinig, 2005). A D-statistic test would have been used to determine if the SLE and 
non-SLE patients had significant differences. The purpose of this step would have been to 





After determining the two cohorts, the risk factors for cancer development were 
used to determine the predicted probability of patients in the SLE cohort and in the non-
SLE cohort to develop the outcome of cancer p(CA). This was going to be done by again 
using a logistic regression model. Next, the relative risk (RR) would have been 
determined using proportional hazards regression (Cox, 1972). The exponentiated 
coefficients on each covariate are an odds ratio of the odds of cancer. A survival analysis 
would have been done using the proportional hazard regression model. 
The use of a high dimensional propensity model allowed the computer program to 
search the database and determine common variables in patients with SLE. In this case, I 
used concurrent diagnoses and medications. Austin (2011) described propensity scores as 
using baseline characteristics to assign patients to a treatment group. In this study, the 
average treatment effect (ATE) was the outcome framework that was used. The ATE is 
the average effect at the population level when the whole group is moved from untreated 
to treated (Austin, 2011). The other framework that could have been used was the 
average treatment effect for the treated (ATT). The ATT is the average effect of 
treatment only for patients who actually received treatment (Austin, 2011). The ATE 
framework was more advantageous in this study because it was more important to 
estimate the effect of cancer development in persons with SLE versus in patients without 
SLE (Austin, 2011).  
Because an observational database was used, the comparative effectiveness of 
covariates was estimated by using the propensity score. This computer-assigned 




either matching or stratification (Curtis, Hammill, Eisenstein, Kramer, & Anstrom, 2007). 
Matching by propensity scores would have matched patients in one treatment group 
directly to a patient in another treatment group solely based on the propensity score. To 
use stratification, the difference in the ATE of the two groups and then the average effect 
would have been calculated within each stratum (Curtis et al., 2007). The number of 
potential patients for inclusion in the study and the use of stratification would have 
increased the probability similarities in the two comparison groups; however, it may have 
been difficult to distinguish the patients from one another (Curtis et al., 2007). Inverse 
Propensity Weighting (IPW) would employ less distributional assumptions about the 
data, prevent additional confounding, could incorporate time dependent covariates, and 
could also manage censored data (Curtis et al., 2007). 
In addition to using propensity scoring to match patients for participation in an 
observational study, the treatment effect could also have been assessed by evaluating the 
multiple variables identified (Heinze & Jüni, 2011). Use of propensity scoring for 
observed covariates for cohort selection in this study would have assisted in decreasing 
the many sources of bias, which result from SLE. Both of these diseases have suggestive 
causes and overlapping factors that may predispose a person to the development of either 
or both diseases. In this study, matching of SLE patients to non-SLE patients using 
conventional randomization measures would have introduced bias into the analyses 
because of the numerous risk factors associated with the outcome of cancer development 




After matching the patients by propensity scores, they were going to be linked to 
the HES database for data on some covariates for reasons described later in the archival 
data section. The cohort design was most suitable for this study to take advantage of all 
available data in the secondary data source CPRD. The cohort design allowed for a 
thorough examination of those persons who developed cancer (Song & Chung, 2010). 
The longitudinal data contained in CPRD was also used in the cohort design as opposed 
to a case control design. 
Probability of Systemic Lupus Erythematosus 
The primary exposure was SLE, and study patients were designated as SLE or 
non-SLE. To calculate the probability of being in the SLE group, I considered the risk 
factors for disease in the propensity score approaches. SLE is most prevalent in people of 
color (e.g.., African, Asian, Indian, or Hispanic) (CDC, 2014). The onset of SLE usually 
occurs between the ages of 16 to 44 years (CDC, 2014). Several exogenous and 
endogenous risk factors contribute to the development of SLE. In a case control study 
conducted in Sweden to explore risk factors associated with the development of SLE, a 
history of hypertension had an odds ratio (OR) of 3.7 (1.4-9.8), history of a reaction to 
the sun had an OR of 2.3 (1.1-4.8), history of a drug allergy had an OR of 3.6 (1.4-9.5), 
and a family history of SLE had an OR of 6.8 (1.4-32) (Bengtsson, Rylander, Hagmar, 
Nived, & Sturfelt, 2002). The presence of these risk factors independently may not result 
in the development of SLE, but a combination of these factors, along with other factors, 
may increase the chances of developing SLE. The high OR for a family history of an 




many autoimmune diseases. Cooper, Dooley, Treadwell, St. Clair, and Gilkeson (2002) 
had similar findings in The Carolina Lupus Study, which was conducted in several 
counties in North and South Carolina. SLE risk factors that were to be used to match the 
SLE and non-SLE cohorts are listed in Table 4.  
Table 4 
SLE Risk Factors 




Year of Birth  
(proxy for age) 
Year of birth Continuous All 
Race Race or ethnicity 






Hypertension Diagnosis of  
hypertension at any 
time 
Yes or No All 
Ultraviolet Skin 
Reactions 
History of skin 
reactions 
Yes or No All 





history of any 
autoimmune disease 
Yes or No All 
History of Allergy to 
Antibiotics 
 
Diagnosis of a history 
of an allergy to an 
antibiotic 
Yes or No All 
History of Shingles or 
Cold Sores 
Self-report or 
diagnosis of shingles 
or cold sores  





 The original plan was to use a logistic regression model to determine the risk of 




determined by matching the covariates between the SLE and non-SLE women in CPRD. 
This calculation would have been used to identify the cohorts of SLE and non-SLE 
patients by matching the risk factors for SLE in both populations. The matched patients 
who fall within the area of common support would have made up the SLE and non-SLE 
cohorts in the study.   
Probability of Cancer 
The outcomes for this study included incident cancer (all types) and cervical 
cancer in particular. Cancer diagnoses were identified in the CPRD and HES. Incident 
cases included cases in which cancer was first diagnosed after the index date in people 
with at least 12 months of registration in the CPRD. The first diagnosis of each cancer 
type was used in instances where a person had multiple cancer diagnoses at different 
times.  
Numerous risk factors may increase the chance of developing cancers (WHO, 
2014). All of the cancer causing risk factors cannot be addressed in one study because of 
the limitations using the existing data in the CPRD and HES database. In this study, 
therefore, I analyzed some of the most common risk factors that are routinely included in 
the medical history of a database, such as the CPRD. The cancer risk factors in this study 
were to include age, tobacco use, human papillomavirus (HPV) infection, Epstein-Barr 
virus (EPV) infection, overweight, pregnancy history, and oral contraceptive (OC) use. 
Age (greater than 65 years) is a risk factor for most types of cancers (CDC, 2014). 
As a person ages, he or she is exposed to a multitude of elements, including 




cancer development (CDC, 2014). The CDC determined that environmental exposures, 
such as air pollution, secondhand tobacco smoke, asbestos, drinking water containing 
large amounts of arsenic, and pesticides, are linked to some cancers such as lung, skin, 
and bladder. Lifestyle elements, such as cigarette smoking, tobacco use, infections, 
radiation, immunosuppressive medicines, diet, alcohol, physical activity, and obesity, are 
either known to increase cancer risk or may affect the likelihood of cancer (CDC, 2014). 
Exposure to tobacco, such as smoking, snuff, and chewing tobacco, is the most 
preventable risk factor for lung cancer, and it contributes to cancers such as mouth, nose, 
throat, larynx, esophagus, liver, bladder, kidney, pancreas, colon, rectum, cervix, 
stomach, blood, and bone marrow (CDC, 2014). Smoking renders a person exposed to 
many cancer-causing chemicals that affect multiple body organs when the chemicals are 
carried via the blood system to the organs. The chemicals act to damage the DNA of cells 
and may contribute to the development of multiple cancers (American Cancer Society 
[ACS], 2014). A history of tobacco use was a cancer risk factor in this study and was 
measured as either yes or no. 
A history of infection with certain viruses and some bacteria can increase the risk 
of developing cancer (CDC, 2014). Infections with certain viruses and bacteria increase 
the risk of cancer development because the infection changes the person’s DNA, and 
changes the behavior of the cells which may cause them to replicate at a rate greater than 
necessary, which is cancer (Cancer Research United Kingdom, 2014). In this study, I 




cancer respectively. HPV is a routine test that is a part of the Papanicolaou (PAP) test for 
females. 
A person that is overweight or has a Body Mass Index (BMI), which is a measure 
of body fat based upon height and weight, has been attributed as a risk factor of 
developing cancer. Being overweight, which can be a result of a poor diet or a lack of 
adequate physical activity, increases the risk of cancers such as colon, uterus, prostate, 
esophagus, breast, and kidney (CDC, 2014). In addition to increased BMIs and increased 
levels of estrogens and insulin, which are also associated with being overweight or obese, 
are some of reasons for increased cancer development (Cancer Research United 
Kingdom, 2014. 
A full-term pregnancy before the age of 17, as compared to a woman who had the 
first pregnancy after the age of 25, and women that had more than three pregnancies are 
associated with an increase in the risk of cervical cancer development (CDC, 2014). 
These two factors increase the risk of cervical cancer development because they increase 
the chances of acquiring a HPV infection due to the potential of the woman having 
unprotected sex with a greater number of sexual partners (ACS, 2014). The hormonal 
changes associated with pregnancy may also contribute to a weakened immune system 
and render the woman susceptible to HPV infection (ACS, 2014).  
Use of estrogen-progestagen OCs over a 5-year or greater period may increase the 
development of cervical cancer (CDC, 2014). A study that analyzed the effect of OC use 
with a background of HPV infection showed that the use of an OC for more than 5 years 




2003). Although HPV exposure is known to be the most important cause of cervical 
cancer, when combined with long-term use of OCs, the relative risk (RR) of cervical 
cancer development was increased as duration of use increased (Smith et al., 2003). 
Smith et al. studied women with cervical cancer with no history of OC use (RR 1.9-2.2) 
compared to women who had used OCs (RR 1.6-3.9) for more than 10 years and found 
the incidence of cervical cancer increased with longer use of OCs. 
Other risk factors could be included but would require a specially designed data 
collection tool. These other factors would include sunlight exposure; ionizing radiation 
exposure; exposure to chemicals such as asbestos, benzene, and cadmium; family history 
of cancer; alcohol use; and diet and physical activity. Because the CPRD does not contain 
the detailed risk factors mentioned, it was not possible to assess these cancer risk factors 
in this study. However, the cancer-associated risk factors that I had planned to be 






Cancer Risk Factors 
Risk Factor Definition How 
Measured 
Study-Relevant 
Associated Cancer  
Age  
(independent) 
Number of years the 
patient has been alive at 




Use of any tobacco 
product such as cigarettes, 
cigars, pipes, snuff, or 
chewing tobacco 





Positive HPV infection at 
any time 
Yes or No Cervical 
EBV Infection 
 
Positive EBV infection at 
any time 
Yes or No Cervical 
Overweight 
 
Having a body mass index 
(BMI) greater than 25  
Yes or No Cancer 
Pregnancy History 
 
Age of 1st pregnancy and 




Use of an OC Yes or No Cervical 
 
Propensity scores were initially going to be used for matching, which would have 
balanced the differences between the patients included in the study. Propensity scoring 
was going to be used to evaluate the multiple variables that could be used to match the 
comparison groups (Heinze & Jüni, 2011). The decrease in the many sources of bias that 
result as related to SLE was to be controlled with the use of propensity scores.   
Treatment effect was going to be assessed by evaluating the multiple cancer-
related risk factors that were identified based on the literature review (Heinze & Jüni, 
2011). Cancer and specifically cervical cancer have numerous strongly suggestive causes 




diseases. None of the previous researchers performed an analysis of the outcome risk 
factors and incorporated this information into the overall measure of association.  
The Database 
Resource constraints encountered with the design choice include the cost to link 
data from the CPRD to other data sources such as the UK cancer registry. This limitation 
resulted in the reliance on HES data rather than data from the cancer registry. CPRD 
(2013) estimated that a link between the CPRD and the UK cancer registry would cost 
approximately $16,000. The cost would pay the CPRD staff to link data in the CPRD 
with data in the cancer registry. Limited funding did not allow me to establish the linkage 
to the UK cancer registry for this study because I was not able to secure the funds from 
my employer, nor was I able to personally support the costs to link the CPRD with the 
UK cancer registry. Because of this resource constraint, I decided to rely on data that 
could be found in the CPRD and HES.  
Time constraints consistent with the design choice included working closely with 
programmers to obtain the proper data from the CPRD. Variables were defined as 
concepts, so that the needed variables could be retrieved from the CPRD. Once obtained, 
additional time was invested to review the data to confirm the inclusion and exclusion of 
variables that were not primary malignancies. In the initial plan, a method to match the 
patients in the other databases would have been implemented once the cohorts were 
selected. The matching would have taken a significant amount of time to ensure that the 
cohorts were matched appropriately. Once matched, several analyses and testing of the 




time required because of the design choice: however, the time constraint was not as high 
as it would have been if raw data had to be collected and assimilated, as in a primary data 
collection study. I recognized there were time constraints associated with this study, and 
allowances had to be factored in to allow the necessary time needed to complete this 
study successfully.   
Frankfort-Nachmias and Nachmias (2008) explained that the non-interventional 
observational study design is made up of two groups for comparison: an exposed group 
and a control group. These two equal groups are either exposed to the independent 
variable (i.e., active disease) or not exposed to it (i.e., no active disease). In this study, the 
comparison groups included patients with SLE and non-SLE patients. The study observed 
whether the presence of SLE had an influence on cancer development (dependent 
variable). Equitable selection of the cohorts decreased bias, which would compromise 
associations detected in the study. Exposure to the treatment allowed for the evaluation of 
the treatment and an assessment to be made of how the treatment would affect the general 
population.  
A quantitative study design was used in this study. A propensity score matched 
retrospective cohort study between a cohort of SLE and non-SLE patients identified in 
the CPRD database was initially planned for this study. The study assessed the 
association of cancer development in patients with SLE. SLE patients consisted of either 
prevalent or incident cases. Non-SLE patients were to be matched with SLE patients 
using the p(SLE). The patients were then to be linked to the UK Death Registry for death 




covariates. The cohort design was most suitable because it allowed multiple outcomes to 
be examined, enabled causality to be assessed, was good for investigating rare exposures, 
and this design would also allow calculation of disease rates in the exposed and 
unexposed patients (Song & Chung, 2010). 
This study assessed the association of cancer in patients with SLE. Because both 
SLE and cancer have many proposed causes, the disease causation theory served as 
framework for this study. The disease causation theory suggests that diseases have many 
causes that cannot be independently attributed to a sole causative agent (Broadbent, 
2009). This multifactorial framework served as the basis to assess the identified cancer-
related risk factors and cancer development in patients with SLE. This framework also 
helped to evaluate the development of particular types of cancers, such as cervical cancer 
in patients with SLE.  
Methodology 
Population 
The source population was obtained from the CPRD. The study population 
included all females with SLE and with no SLE. All female SLE patients with a diagnosis 
of SLE included in the area of common support in CPRD (i.e., prevalent and incident 
cases) were included. Drug-induced lupus cases were excluded because they are of a 
different etiology than SLE. Patients with cutaneous lupus were excluded because they 
do not follow the same pathophysiology as SLE. The only restriction on age was that they 




diagnosis prior to their registration in the CPRD, prior to their current registration date 
(CRD), were likely to get a cancer diagnosis entered within the first few months after 
registration, which results in the incidence of diseases being overestimated during this 
period (Lewis, Bilker, Weinstein, & Stron, 2005). Therefore, incident cases were defined 
as those with the first diagnosis of SLE after the latest of the CRD and the practice up-to-
standard (UTS) date plus 12 months. Prevalent cases were defined as those that had the 
first SLE diagnosis prior to the later of the CRD date and the UTS date plus 12 months. 
The index date for incident cases was the date of SLE diagnosis. The index date for the 
prevalent case was the later of the CRD date and UTS date plus 12 months. The 
comparison group was the non-SLE cohort selected from CPRD. Patients must not have 
had an SLE diagnosis at any time during the period considered for the SLE cohort. Non-
SLE patients were to be matched individually to SLE patients based upon the propensity 
weights. 
Sampling and Sampling Procedures 
All female SLE and non-SLE patients in the CPRD who fell within the area of 
common support were to be included in the study. An initial assessment of the CPRD 
database revealed that approximately 4,000 female patients in CPRD had SLE (both new 
and prevalent cases) and of those 4,000, roughly 2,000 could be linked to other registries. 
The necessary sample size was calculated using clincalc.com, which was provided by 
Clincalc, LLC. To determine the sample size needed adequately to power the study, the 
overall incidence of cancer in females in the United Kingdom used was 266/100,000 or 




SLE women in CPRD used was 18.88/1000 or 1.89% (SAEfetyworks, 2015). The 
probability of type-1 error was 0.05 and the power was set at 0.80 with the enrollment 
ratio being 1 or equal cohort sizes (see Table 6). Using these numerical settings, it was 
calculated that the total study size needed to have sufficient statistical power to detect a 
difference (type II error) was 1,276 total with 638 patients assigned to each of the 
cohorts, SLE and non-SLE.  
Table 6  
Parameters Used for Sample Size Calculation 
Incidence, group 1(non-SLE) 0.27% 






The CPRD is funded by the National Health Services (NHS) National Institute for 
Health Research (NIHR) and Medicines and Healthcare products Regulatory Agency 
(MHRA). CPRD has been used in more than 890 clinical reviews and papers, and the 
database is considered the gold standard by many because the high compliance of health 
care providers entering the data into the database (Clinical Practice Research Database, 
2013). The CPRD is managed by a group that serves the general practitioners who enter 
the data into the database, and the managing group serves researchers by anonymizing the 
data so that it can be linked to other databases (CPRD, 2013). The CPRD is a combined 




of Health’s NIHR Research Capability Program (RCP) into a secure electronic research 
database. The NHS assigns a unique patient identifier number that is only used by a 
trusted third party for linkage, and it is never released to researchers (CPRD, 2013). This 
anonymized identification number ensures that linkages to other database are valid while 
maintaining privacy for the patient. Access and use of CPRD data are controlled under 
the laws of the United Kingdom and Europe.  
Data in the CPRD are available online after completion of a 2-day training 
program provided by the CPRD research team. The training provides background 
information about CPRD, data fields contained in the database, linkages available, data 
entry information that practitioners follow, and services that CPRD can provide. There 
are costs for accessing the CPRD data to cover services provided by the CPRD Research 
Team. These costs are either paid by individuals, academic institutions, or business 
entities. My access to the CPRD was granted by my employer. The information obtained 
from this study will be useful as background information for patients with SLE. My 
employer conducts research to develop medicines, and findings from this study will be 
helpful in decisions related to studies being conducted for drugs that could potentially be 
used as a treatment for SLE. The company had already paid for a number of people that 
could have access to the CPRD, and I was approved to be one of the persons who could 
have access for the company; therefore, I did not have to pay out of my pockets for 
access to the CPRD. There are legal agreements that cover all aspects of the use of the 




There are linkages already established with the Office of National Statistics 
(ONS), which contains mortality data. These data are available to researchers after a 
research project is approved by the Independent Scientific Advisory Committee (ISAC) 
for MHRA database research (CPRD, 2013). The ISAC is an appointed expert advisory 
body that provides advice on research requests to access CPRD (CPRD, 2013). A request 
to ISAC must include the project’s methodology, information on the medical, statistical, 
and epidemiological aspects of the proposed study (CPRD, 2013). ISAC can request 
additional information needed in making a determination whether the proposed study in 
CPRD will be approved or denied. All investigators and collaborators are included in the 
application to have the protocol approved by ISAC.  
The CPRD is funded by the NHS, NIHR, and the MHRA (CPRD, 2013). The 
CPRD services are designed to improve the way NHS clinical data can be linked to 
enable many types of research and deliver useful research outputs (CPRD, 2013). Non-
SLE patients were to be matched with SLE patients on propensity scores. A link to data 
in the HES database was made to obtain data on diagnosis of malignancies. The cohort 
design was most suitable for this study to take advantage of all available data in CPRD 
and HES database. Types and sources of information or data were CPRD provided 
demographic and diagnostic data on patients with SLE, and HES provided information 
about SLE diagnosis, cancer diagnoses, diagnostic and laboratory information. 
Operationalization 
HES is a data warehouse that contains details of approximately 125 million 




National Hospital Services hospitals in England (Health & Social Care Information 
Center [HSCIC], 2014). Data entered are administrative in that they allow hospitals to be 
paid for the care they deliver (HSCIC, 2014). Although administrative in nature, HES can 
be used to monitor trends and patterns in hospital activity, to assess efficient delivery of 
care, and to inform patient choice (HES, 2014). The HES database was developed in 
1987 after a report that collected hospital information was commissioned by the NHS and 
published. The 1987 report was the start of a database that contained information 
compiled for each hospital admission and used to assess the severity of SLE disease 
activity for patients. Data in HES are collected monthly and are accessible via the 
Internet. 
Data Analysis Plan 
Research Questions 
RQ1: Is the risk of cancer development increased in SLE patients compared to 
non-SLE patients? 
Ho1: There is no increased risk of cancer development in SLE patients compared 
to non- SLE patients for overall cancer risk and cervical cancer risk. 
Ha 1: There is an increased of cancer development in SLE patients compared to 
non-SLE patients for overall cancer risk and cervical cancer risk. 
Planned Methodology: Conditional Logistic Regression  
To measure incidence of cancer, patients were followed from the index date until 




conditional logistic regression model would have allowed an analysis of binary outcome 
data with one or more predictors and where observations were not independent, but were 
matched (Statsdirect, 2014).  
Planned Methodology: Proportional Hazard Regression 
A survival analysis was initially planned, using the proportional hazard regression 
model with the index date for the SLE cohort being the earliest date indicated in CPRD 
presumed as being the onset date. The index date for the non-SLE cohort would be the 
date of enrollment in CPRD. The identified risk factors were to be analyzed to determine 
their impact on the development of cancer in patients with SLE. The Cox proportional 
hazard model (backward method) was initially planned to be used to examine the relative 
effect of each covariate on the incidence of cancer. All analyzes would be performed 
using Statistical Analysis System (SAS) version 9.2. SAS is software developed at North 
Carolina State University in 1976, and the software can be used for advanced analytics, 
data management, predictive analysis, and business intelligence (Statistics Solutions, 
2014). 
The original plan was to have risks for each cancer site to be determined by 
measuring the relative risk, which is the ratio of the probability of an event occurring in 
the exposed group to the likelihood of the event occurring in the comparison or 
unexposed group to the expected number of cancers. A cohort type study allowed 
calculation of incidence, which could be used to calculate relative risk by dividing the 
cumulative incidence in the exposed by the cumulative incidence in the unexposed. This 




The cohort design best used the benefits of using the longitudinal data contained in 
CPRD. All analyzes were performed using SAS version 9.2.  
In multivariable analysis, consideration would be given to all cancer and cervical 
cancer known to be related to SLE as the outcome. The primary exposure was SLE or 
non-SLE. In addition to overall cancer development, a particular association of cervical 
cancer was included. Depending on the power, some cancers may need to be grouped 
together to increase power. Because I eventually assessed overall cancer and cervical 
cancer, it was not necessary to group cancers. Sensitivity analyses using different 
definitions for latency were going to be conducted to take latency of cancer into account 
(e.g., 1, 2, 3, 5 years). Although the size of the SLE cohort in CPRD is substantially 
larger than in many previous studies, an attempt was be made to take latency for cancer 
into account: however, this would be dependent upon the effective sample size and 
commensurate level of power. 
Threats to Validity 
The validity of this study depended on the accuracy and reliability of the 
information entered into the database. SLE is a difficult diagnosis to make, and there may 
be a risk of including non-SLE patients. As mentioned earlier, cases that were diagnosed 
within 6 months were to be excluded because both SLE and cancer have similar 
symptoms. They were excluded because it was impossible to determine which diagnosis 
occurred first. Allowing cases where it is unknown whether the SLE or cancer was 





The IRB review and approval protected the study and the university by 
independently reviewing the methodology being used in the study to determine if there 
was any potential for harm to anyone participating in the study (Rudestam & Newton, 
2007). This study underwent IRB review and was found that it did not pose an ethical 
concern because it was a retrospective study using secondary data from CPRD; the IRB 
approval number is 06-03-15-0149603. The study retrospectively assessed the association 
of cancer development in persons with SLE disease. The patients were linked to the HES 
database for additional data on the variables. All data were historical, and all patients 
remained anonymized during all reviews. All data will be stored on my computer at home 
and at my place of employment for 5 years after the study is complete. I have access to 
these data as well as my employer.  
This study involved research to obtain information to assess a public health issue, 
cancer development in SLE patients. The study did not involve the provision or 
withholding of a medical intervention. This retrospective study did not have people 
participating in it; therefore, no determination of full disclosure of information to 
potential study participant was needed, which is an activity of the IRB.  
Summary 
It is uncertain if SLE is associated with a higher rate of cancer. Previous research 
in this area has been based upon small study samples; cohorts that were not closed, which 
could increase the number of patients lost to follow-up; and the studies have lacked 




et al., 2008). Previous studies were underpowered; therefore, they did not allow a 
conclusive determination to be made about whether a relationship exists between SLE 
and cancer (Bernatsky et al., 2005). The smaller sample sizes were not conducive to an 
examination of cancers that occur less frequently. The examination of less frequent 
cancers is important because of the various associated risk factors, etiology, and 
pathophysiology of these cancers.   
This study used a large, population-based database to test the relationship between 
SLE and cancer in a large population. The larger sample size in this study allowed 
examination of cancers that occur at a lower incidence. This study also examined the 
incidence rates of various cancer types found in patients with SLE. Non-SLE patients 
were initially going to be matched with SLE patients using IPWE. All participants in this 
study had to be at least 18 years of age and the study included a period of 10 years up to 
2014. The patients were linked to the HES database so that data on other covariates could 
be collected. The cohort design allowed me to take advantage of all available data in 
CPRD and HES. 
All SLE subjects in CPRD were included in the analysis. Overall incidence of 
cancer was the main outcome; in addition, the risk of developing cervical cancer was 
examined. Cancer diagnoses identified in the CPRD and HES were assessed to obtain 
additional information about the covariates. Year of birth, race, hypertension, ultraviolet 
skin reactions, family history of SLE or other autoimmune diseases, history of allergy to 
antibiotics, and history of shingles or cold sores were the covariates that I initially 




probability of cancer were age, tobacco use, HPV infection, EBV infection, overweight, 
pregnancy history, and contraceptive history. Data on the covariates were obtained from 
the CPRD and HES.  
The disease causation theory served as framework for this study. This theory 
acknowledges the understanding that SLE and cancer develop because of several factors 
together rather than any one single factor leading to the development of either of these 
diseases. This framework served to assess the development of specific types of cancers, 
such as cervical cancer, in persons with SLE. Statistical analyzes were performed using 
SAS.  
In the next chapter, a review of the purpose of the study, research questions, and 
hypotheses will be presented. A detailed discussion of the descriptive and demographic 
characteristics of the cohorts will be given along with a correlation of the sample 
population with the population of interest. The results of all analyses performed will be 
presented and details of any challenges encountered with the implementation of the 
study. Descriptive characteristics and assumptions will be evaluated and all findings will 
be reported. Tables and figures will be displayed to illustrate the results as appropriate. A 
thorough examination of steps taken to execute the study will be presented along with a 





Chapter 4: Results 
Introduction 
Chronic non-communicable diseases such as SLE account for a significant 
number of deaths, which are often a result of the impact of SLE on various organ systems 
(Manzi, 2009). The increased control of SLE flares has decreased the devastation on 
organ systems in the body and has resulted in decreased deaths due to SLE activity. This 
increased control of SLE disease activity has now allowed researchers to study other 
areas of concern relative to persons with SLE (Manzi, 2009). The purpose of this study 
was to assess the association of cancer in patients with SLE. Because both SLE and 
cancer have a plethora of proposed causes, the disease causation theory was most 
appropriate to serve as framework for this study. According to the disease causation 
theory, diseases have many causes that cannot be independently attributed as a sole 
causative agent (Broadbent, 2009). This multifactorial framework served as a basis to 
assess the development of cervical cancer in patients with SLE 
A high dimensional propensity weighted, retrospective cohort study among SLE 
and non-SLE female patients identified in the CPRD database was used to assess the 
association of cancer development in patients with SLE. Female SLE patients with 
prevalent and/or incident cases were included in the study. Non-SLE patients were 
matched with SLE patients in CPRD. The main exposure for this study was SLE 
(exposed) and non-SLE (unexposed) study patients, which was designated as SLE or 




cancer type was used in instances where the person had multiple cancer diagnoses at 
different times.  
Research Questions and Hypotheses 
The research questions and hypotheses for this study were 
RQ1: Is the risk of cancer development increased in SLE patients compared to non-SLE 
patients? 
H01: There is no increased risk of cancer development in SLE patients compared to non-
SLE patients for overall cancer risk as compared to non-SLE population and 
cervical cancer risk as compared to non-SLE population. 
Ha 1: There is an increased risk of cancer development in SLE patients compared to non-
SLE patients for overall cancer risk as compared to non-SLE population and 
cervical cancer risk as compared to non-SLE population; 
In this chapter, the data collection details will be described. The plans for 
collecting the data were discussed in Chapter 3, and any deviations from those plans will 
be detailed in this chapter along with rationale for the deviation. The demographics of the 
patients will be presented, and an analysis of the patients’ proportionality to the larger 
population will be discussed. The results of the analyses that justify the covariates that 
were used in the model will be provided and discussed. The statistical analyses that were 
used to determine and extract the sample populations will be presented along with the 
findings from the analyses that were performed. No additional statistical tests emerged 
from the analysis of the main hypotheses. Tables and figures will be included in this 




research questions will be summarized, and the prescriptive materials that will be 
presented in Chapter 5 will be introduced. 
Data Collection 
The source population for this study was patients in CPRD. The study population 
included females with SLE. An inverse probability of treatment weights (IPTW) was 
performed because the estimate of interest was the ATE or the effect that would be seen 
if both the SLE and non-SLE cohorts received the same concurrent diagnoses and the 
same concomitant medications (Harder, Stuart, & Anthony. 2010). The IPTW allowed all 
of the study patients (SLE and non-SLE) to be weighted up to represent the entire study 
population (Harder et al., 2010).  
All female SLE patients with a diagnosis of SLE (prevalent and incident cases) 
and all non-SLE females in the area of common support in CPRD were included in the 
study using propensity scores based on SLE risk factors. Patients had to be at least 18 
years of age to be included in the study. Through CPRD, patients were followed for up to 
15 years. The index date for this study was the date of SLE diagnosis. The comparison 
group was the non-SLE cohort selected from CPRD. Patients must not have had an SLE 
diagnosis at any time during the period considered to be included in the non-SLE cohort. 
In Chapter 3, the data collection plan was developed based upon predefined 
covariates. These variables were selected from a review of published literature on risk 
factors associated with developing SLE and risk factors associated with the development 
of cancer. The predefined risk factors were to be used to first calculate the probability of 




reaction to the sun, and a family history of SLE or other autoimmune diseases were to be 
used as risk factors to match the SLE and non-SLE cohorts. Database limitations 
prevented me from using all of the risk factors. Later I will present the actual risk factors 
that were used to match the SLE and non-SLE cohorts.  
Once the SLE and non-SLE cohorts were identified, the original plan was to 
determine the probability of cancer in both cohorts by using the same process. Risk 
factors for cancer development, as identified in literature reviews, were to be used to 
match the SLE and non-SLE cohorts. This would create a comparable population by 
controlling for prediction of SLE and the covariates that were chosen. Recognizing that 
all of the cancer causing risk factors could not be addressed in one study, some of the 
most common risk factors associated with developing cancer, such as increased age 
(greater than 65 years), tobacco use or exposure, HPV infection, EBV infection, being 
overweight, pregnancy history, and OC use, were to be used. Later, I will present the 
method actually used to assess cancer in the SLE and non-SLE cohorts. 
Upon attempting to use the predefined risk factors to identify the SLE and non-
SLE cohorts, I realized that CPRD did not identify race in the database. Age could be 
determined, but history of hypertension, history of a reaction to the sun, and a family 
history of SLE or other autoimmune diseases were not standard fields in CPRD. The lack 
of these data fields led me to re-evaluate the methods for selecting the cohorts for this 
study. A high dimensional propensity score model was used instead of the original study 
plan, which was to assign a weight to the predefined variables selected based upon the 




In the high dimensional propensity model, a computer program was used to assign 
weights to variables based upon the analyses of the common variables related to SLE that 
were found in the database (Schneeweiss et al., 2009). In this study, I used the most 
common diagnoses and most commonly associated prescriptions used by persons with 
SLE. The selected covariates included the top 100 diagnoses and prescriptions that were 
found most frequently in the database for the SLE population. The covariates (concurrent 
diagnoses and concomitant medications) were then assimilated into a propensity score 
based confounder adjustment model (Schneeweiss et al., 2009). The diagnoses and 
medications were ranked amongst the SLE population in CPRD, and then they were 
matched with the non-SLE population in CPRD. The seven steps used to implement the 







Figure 1. Flow chart for a basic high-dimensional propensity score algorithm 
Note: (modified from Schneeweiss et al., 2009, Copyright © Lippincott Williams & 
Wilkins). 
 
The CPRD is a health care use database, so data collected were not geared toward 
assessing clinical disease development and severity, such as the covariates that had been 
identified from the literature review. However, the CPRD does contain a large amount of 
data that can be used as proxy to describe disease status. In this study, the SLE and non-
SLE cohorts were selected by using the concurrent diagnoses that were commonly 
diagnosed in patients with SLE, as proxy. After selecting the female patients with SLE in 
CPRD, the most common concurrent diagnoses that SLE patients had were selected. The 
concurrent diagnoses were used because SLE is usually accompanied by other disorders 
Specify data dimensions (i.e., diagnoses, 
concomitant medications)
Identify empirical candidate covariates
Assess recurrence
Prioritize covariates
Select covariates for adjustment
Estimate exposure propensity score




because of the nature of the disease process of SLE and its impact on all systems of the 
body.  
The top 100 diagnoses that were given to persons with SLE in the CPRD were 
selected. The diagnoses that were identified were ranked in the order of how often the 
diagnosis occurred in SLE patients. The concurrent diagnoses were described in groups 
of similar types of events. Of the 100 top concurrent type of diagnoses reported for 
patients with SLE in the CPRD, approximately 26% of the diagnoses were some form of 
pain, such as headache, general pain, or specific events of pain of various body areas. 
Pain is a common manifestation of SLE because the body produces antibodies against 
itself. The next largest group of events was infections and inflammations, which 
accounted for 15% of the concurrent diagnoses. Inflammation is usually an indication of 
some type of infection. In patients with SLE, inflammation can be a result of the 
breakdown of body processes because of SLE, or it could be a result of the enhanced 
development of infections because of using corticosteroids and other medications to treat 
the symptoms of SLE. The remainder of the concurrent events was found in the category 
of respiratory events (9%), rashes or skin disorders (8%), female-specific events (7%), 
gastrointestinal events (6%), malaise (5%), urinary events (5%), and cardiac events (3%) 
as displayed in Table 7. All of the concurrent diagnoses before the index date were 
descriptive of patients with SLE and the pathophysiology of the disease. A random date 







Concurrent Diagnoses in SLE Patients 




Rash/Skin Irritations 8% 








The other proxy used to describe the SLE population was medications that the 
SLE patients in CPRD were prescribed prior to the index date. The 100 most frequently 
prescribed concomitant medications for SLE patients in CPRD were identified. The top 
10 frequently prescribed concomitant medications with their drug class in parenthesis 
were acetaminophen (pain), amoxicillin (antibiotic), prednisolone (corticosteroid), 
codeine (pain), influenza virus vaccine (prophylactic), diclofenac (inflammation), 
hydroxychloroquine (antimalarial), ibuprofen (pain/inflammation), hydrocortisone 
(corticosteroid), and trimethoprim (an antibiotic) (see Table 8). All of the concomitant 
medications identified by the computer search were in alignment with the manifestations 
of the SLE disease process. Other concomitant medications identified were medications 






Frequently Prescribed Concomitant Medications in SLE Patients 
Rank Medication Drug/Indication 
1 Acetaminophen Pain/Inflammation 
2 Amoxicillin Antibiotic 
3 Prednisolone Corticosteroid 
4 Codeine Pain 
 
A medication specifically for the treatment of SLE was not available until 2013 
when Benlysta™ was approved to be sold on the market. Up until 2013, medications 
prescribed for SLE patients were for palliative treatment of symptoms that the disease 
exhibits and not to cure the disease itself. As noted by the 100 most prescribed 
medications identified in the CPRD for the high dimensional propensity score modeling, 
none of the medications were specifically for the indication of SLE.  
Pain and inflammation were the most commonly prescribed medications for 
patients with SLE in the CPRD. Pain and inflammation of the joints are common 
manifestations of SLE because the body produces antibodies that work against itself. 
Medications for pain and inflammation were the most commonly prescribed class of 
medication for patients with SLE in CPRD. Corticosteroids were the second most 
prevalently prescribed class of medication. Steroids are used to decrease swelling, 
warmth, tenderness, and pain that are associated with inflammation. Long-term steroid 




general. This immune system suppression secondary to corticosteroid use is the reason 
that antibiotics and anti-infectives are the third most frequently prescribed class of 
medication in the SLE population in CPRD.   
The Sample 
Once the risk factors that contribute to the development of SLE were determined 
and the cohorts were identified, an OR estimate was performed to determine if there was 
an increased probability of incurring SLE p(SLE) if the patient had been diagnosed with 
certain concurrent diseases. Another estimate was run to determine if there was an 
increased p(SLE), if the patient had been prescribed particular medications (Le, 2009). Of 
the 100 concurrent diagnoses made to SLE patients found in CPRD, the 10 diagnoses 
with the highest probability of being made in SLE patients are shown in Table 9. These 
findings are consistent with the earlier noted top 10 types of diagnoses found, with the 
greatest number of diagnoses being some type of pain, infection, and rash. Because the 
population studied was entirely female, female events are noted to be concurrently 






Diagnoses with the Highest Probability of Being Made in SLE Patients 
  95% Wald Confidence Limits 
Diagnosis Point Estimate Low High 
Herpes Zoster 27.428 21.059 35.723 
Irritable Bowel 
Syndrome 
16.431 13.63 19.808 
Generalized aches 
and pains 
1.906 1.6 2.27 
Cardiac disease 
monitoring 
1.877 1.541 2.285 
Breast lump 
symptom 
1.558 1.283 1.893 
Vomiting 1.528 1.146 2.036 
Arthritis 1.51 1.266 1.801 
Chest pain 1.461 1.312 1.627 
Hemorrhoids 1.461 1.213 1.76 
Rash 1.455 1.307 1.619 
 
 
Of the 100 concurrent medications prescribed to SLE patients found in CPRD, 
the10 medications with the highest probability of being prescribed to SLE patients are 
shown in Table 10. An antimalarial (hydroxychloroquine) was the highest prescribed, 
followed by a disease modifying antirheumatic drug (azathioprine), then a corticosteroid 
(prednisolone), followed by a blood thinner, antihypertensive, a NSAID, a thyroid 
hormone, a topical corticosteroid, another DSAID, and an iron supplement. These 






Medications with the Highest Probability of being Prescribed to SLE Patients 
  95% Wald Confidence Limits 
Medication Point Estimate Low High 
Hydroxychloroquine 78.859 70.846 87.778 
Azathioprine 4.589 3.885 5.42 
Prednisolone 3.193 2.891 3.525 
Warfarin 2.847 2.43 3.334 
Nifedipine 2.026 1.735 2.365 
Aspirin 1.579 1.4 1.781 
Levothyroxine 1.443 1.249 1.668 
Clobestasol 1.411 1.202 1.657 
Diclofenac 1.362 1.245 1.489 
Ferrous sulfate 1.303 1.171 1.45 
 
It is important to note that propensity score matching is somewhat different from 
matching that occurs in a randomized study; propensity score matching only balances the 
observable whereas, in a randomized study both observable and unobservable 
distributions are balanced (Lee, 2013). Because the propensity score was used for the 
purpose of balancing, it was imperative to run a test to determine whether the propensity 
score effectively balanced the covariates used to identify the SLE and non-SLE cohorts. 
This balance statistic ensured that the propensity score had the same distribution for both 
the SLE group and the non-SLE group. I had to ensure that the treatment medications and 
the concurrent diagnoses found in CPRD were distributed in a balanced manner amongst 
the SLE and non-SLE cohorts.  
An IPTW was performed because the estimate of interest was the ATE or the 
effect that would be seen if both the SLE and non-SLE cohorts received the same 




demonstrated in Figure 2, the IPTW weighting technique assigns each individual patient 
a weight or propensity score that is the inverse probability of receiving the treatment that 
they actually received; this allows all of the study patients to be weighted up to represent 
the entire study population (Harder et al., 2010).  
  
 




Heavily weighted covariates would create bias because they would have 
significantly more influence in determining the balance of the cohorts. Simply removing 
the covariates with the largest weights would create additional bias because the covariates 
with the largest weights are the best predictors of the outcome that is being compared. 
Therefore, a stabilization technique was applied to decrease the variability of the weights. 
The treatment and comparison weights were each independently multiplied by a constant 
that was equal to the expected value of being in either group (Harder et al., 2010). Once 
the weights were stabilized by the computer program, a technique known as trimming 
was used to minimize the influence of any remaining outlying weights.  
Exposed individuals IPTW = 1 / ρi (a)
Comparison patients IPTW = 1 / (1-ρi)




Trimming limits the stabilized weight by shortening them to within a specific 
range. The goal was to select the trimmed percentile that is most aligned with the 
baseline. Figure 3 displays the balance of the diagnoses at baseline, with no trim, at 99% 
of SLE trimmed, and at 95% trimmed. A 95% trim was selected because that was most 
aligned with the baseline as depicted in Figure 4 with the no trim and 99% trim graphs 
removed so that the balance can be seen clearer. The 95% trimmed weights align most 
consistently with the baseline weight and therefore, a 95% trimming will be used for the 




























































Figure 4. Balance of 95% trimmed weights for diagnoses using IPTW 
 
Figure 5 and Figure 6 display the concomitant medications prescribed for SLE 
patients in CPRD with the balance of the IPTW weights at baseline, with no trimming, at 
99% and at 95% trimmed. 
 
 



































































































Figure 6. Balance of 95% trimmed weights for concomitant medications using IPTW 
 
Using the concurrent diagnoses and concomitant medications for a high-
dimensional propensity model rendered an initial SLE population of 3,362 and a non-
SLE population of 2,719,084 in CPRD, using IPTW with a 95% trimming to best balance 
the weights of the covariates. The IPTW was then applied to the SLE and non-SLE 
cohorts that had been identified in CPRD. This application of the IPTW and the trimmed 
covariates rendered a SLE cohort of 3,025 and a non-SLE cohort of 180,555 patients.  
The sample obtained is an accurate representative to the SLE and non-SLE 
populations in the general population. The SLE and non-SLE populations included in the 
sample are balanced in the concurrent diagnoses made to each population and they are 
balance in the concomitant medications prescribed to them. These balances make both 


















































The equal exposure to potential covariates will allow a more equitable assessment of 
malignancy development amongst the two groups. 
To identify primary cancers in CPRD, the Observational Medical Outcome 
Partnership (OMOP) vocabulary was used to identify the concept of cancer. The concept 
names of neo, mal, and can were used to identify any terms with any of those series of 
letters. The initial findings included a great number of events that were (a) benign events 
(curable by removal), (b) events that were potential precursors to malignancies, and (c) 
not malignancies. Because we only want to include malignancies in this study, and more 
specifically, the first malignancy diagnosed, we then added pri to the search. For this 
reason, secondary malignancy sites were not included nor were any of the previously 
mentioned conditions that were not malignancies. As to be expected, the greatest number 
of malignancies included female specific cancers such as breast, uterus, and cervix. The 
next largest group of malignancies was in the digestive system. The number of cervical 
cancers found in the non-SLE cohort was significantly greater than the number found in 
the SLE cohort. A depiction of the malignancies, of which there were at least 10 or 
greater events, found in the SLE or non-SLE cohorts in CPRD are listed in Figure 7 and 















Malignancies by Body System 
  SLE (n) Non-SLE (n) 
Female Reproductive Cancers 
Malignant neoplasm of female breast 
Malignant neoplasm of corpus uteri, excluding isthmus 
Primary malignant neoplasm of uterine cervix 
Malignant neoplasm of endometrium of corpus uteri 
Malignant tumor of cervix 
Malignant neoplasm of body of uterus 
Carcinoma of cervix 
Primary malignant neoplasm of vagina 




















Primary malignant neoplasm of colon 
Primary malignant neoplasm of sigmoid colon 
Malignant tumor of esophagus 
Primary malignant neoplasm of rectum 
Primary malignant neoplasm of esophagus 
Primary malignant neoplasm of stomach 
Malignant tumor of intestine 
Primary malignant neoplasm of cecum 
Primary malignant neoplasm of rectosigmoid junction 
Adenocarcinoma of rectum 
Malignant tumor of cecum 
Malignant tumor of ascending colon 
Primary malignant neoplasm of transverse colon 
Primary malignant neoplasm of lower third of esophagus 
Primary malignant neoplasm of anus 
Carcinoma liver and/or biliary system 






































Malignant melanoma of skin 
Squamous cell carcinoma of skin 








Primary malignant neoplasm of bladder 






Primary malignant neoplasm of pancreas 
Primary malignant neoplasm of ovary 
Malignant tumor of ovary 
Primary malignant neoplasm of thyroid gland 
Primary malignant neoplasm of head of pancreas 















 SLE (n)          Non-SLE (n) 
Nervous System 





















Malignant neoplasm of middle lobe, bronchus or lung 
Malignant neoplasm of main bronchus 
Primary malignant neoplasm of pleura 
Malignant neoplasm of upper lobe of lung 













Figure 8. Number of malignancies by body system 
  



























A binary logistic model was used to describe the fit for using the covariates to 
select the SLE and non-SLE cohorts found in CPRD. IPTW was the weight variable and 
there were two levels of responses, yes (has cancer) or no (does not have cancer). The 
regression parameters were estimated using Fischer’s scoring method. The total number 
of observations read and used was 183,580. The unweighted SLE cohort yielded 3025 




Unweighted SLE (1) and Non-SLE (0) Cohorts in CPRD 
Table of LUPUS by CANCERFLAG 
  CANCERFLAG(CANCRFLAG) 
Total 0 1 
LUPUS(LUPUS)   





2906 119 3025 
    




In the unweighted cohorts, the relative risk of developing cancer due to having 






Table 13  
Statistics for Table of LUPUS by CANCERFLAG (unweighted) 
Estimates of the Relative Risk (Row1/Row2) 
Type of Study Value 95% Confidence Limits 
Case-Control  
(Odds Ratio) 
3.3868 2.8059 4.088 
 
Once the computer generated weights were applied, the SLE cohort weight was 
18055.7 and 645580 in the non-SLE cohort (Table 14). 
 
Table 14 
IPTW weighted SLE (1) and Non-SLE (0) Cohorts in CPRD 
    
  CANCERFLAG (CANCERFLAG) 
Total 0 1 
LUPUS(LUPUS)   





450015 15582.9 465598 
    




In the weighted cohorts, the unadjusted relative risk of developing cancer due to 






Table 15  
Statistics for Table of LUPUS by CANCERFLAG (weighted) 
Estimates of the Relative Risk (Row1/Row2) 
Type of Study Value 95% Confidence Limits 
Case-Control (Odds Ratio) 2.7385 2.6238 2.8581 
 
An assessment of the fit of the binary logistic model against the data revealed that 
it was a good fit as demonstrated by the values of the intercept only versus the intercept 
and covariates in the three methods used to assess the model fit. Akaike Information 
Criterion (AIC) was used for the comparison of non-nested models on the same sample 
(University of California Los Angeles. 2015). The Schwarz Criterion (SC) and the AIC 
both penalize for the number of predictors in the model and the smallest SC and AIC are 
the most desired model (University of California at Los Angeles. 2015). The -2 Log L is 
used to test hypotheses in nested models and there is no real value in the numbers 
(UCLA. 2015). The intercept only column represents the response variable with no 
predictors in the model whereas the intercept and covariates column represents criterion 
statistics for the fitted model, which includes all independent models and the intercept 
(Table 16) (UCLA. 2015). For each of the criterion used, the lower value of the intercept 
and covariates versus the intercept only confirms that the binary logistic model used was 







Model Fit – SLE & Non-SLE (unweighted) 
Criterion Intercept Only 
Intercept and 
Covariates 
AIC 165773.2 163109.3 
SC 165783.3 163129.6 
-2 Log L 165771.21 163105.3 
 
 
With no adjustment for age, the predictor variable of SLE indicates that a patient 
with SLE is 2.7 times more likely to develop cancer than is a non-SLE patient with 95% 
Confidence Limits (Table 17).  
Table 17 
Odds Ratio Estimates-SLE 
Effect Point Estimate 
95%Wald Pr > ChiSq 
Confidence Limits  
LUPUS 2.738 2.623 2.857 <.0001 
 
The fit of the binary logistic model was assessed with the variables of age. The 
binary logistic model was again a good fit as demonstrated by the lesser value of the 
intercept and covariates versus intercept only value for each of the three methods used to 
assess the model fit, AIC, SC, and -2 Log L (see Table 18). The greater difference in the 
intercept and the intercept wand covariates indicates that with the addition of age, the 





Table 18  
Model Fit – SLE and Age 
Criterion Intercept Only 
Intercept and 
Covariates 
AIC 165773.2 149047.2 
SC 165783.3 149077.5 
-2 Log L 165771.21 149041.2 
  
 
With adjustment for age, the predictor variable of SLE indicates that a patient 
with SLE is still 2.7 times more likely to develop cancer than is a non-SLE patient with 
95% confidence limits (Table 19). Age was not a significant factor in whether the SLE 
patients developed cancer. 
 
Table 19 
Odds Ratio Estimates-SLE & AGE 
Effect Point Estimate 
95% Wald  
Confidence Limits Pr > ChiSq 
LUPUS 2.669 2.556 2.788 <.0001 
AGE 1.052 1.051 1.053 <.0001 
 
All of the original covariates related to cancer development were not identifiable 
in CPRD because of the limitations of using a database that was designed to collect 
universal health information in the United Kingdom. 
Odds ratio estimates were run to include age, contraception use, pregnancies, 
obesity, and smoking history (Table 20). Having had a pregnancy had the greatest effect 




greatest effect on cancer development was having SLE, followed by obesity, use of oral 
contraception, age, and then smoking. It was quite surprising that smoking actually 
seemed to have a protective effect on cancer development. These effects are stated with 
95% confidence limits that with repeated trials; we would obtain the same results for each 
covariate. No additional post-hoc analyses were performed. 
Table 20 
Odds Ratio Estimates for Age, Contraception Use, Pregnancies, Obesity, and Smoking 
History 
Effect Point Estimate 95% Wald Confidence Limits 
 
Pr > ChiSq 
Lupus 2.906 2.781 3.035 <.0001 
Age 1.06 1.058 1.061 <.0001 
Contraception 1.602 1.521 1.687 <.0001 
Pregnancy 3.146 2.98 3.322 <.0001 
Obesity 2.476 2.4 2.555 <.0001 
Smoking history 0.793 0.765 0.823 <.0001 
 
Summary 
This study sought to assess the association of cancer development in patients with 
SLE. In evaluating research question one, the risk of cancer development is increased in 
SLE patients compared to non-SLE patients. In the weighted cohorts, the unadjusted 
relative risk of developing cancer due to having SLE was 2.74. The greatest number of 
malignancies was female specific cancers such as breast, uterus and cervix followed by 
malignancies of the digestive system. This finding is congruent with findings from 




compared to persons without SLE (Bernatsky et al., 2005; Kiss et al., 2010; Parikh-Patel 
et al., 2008). 
The balance created by using the IPTW to select the SLE and non-SLE cohorts 
attributed to a more accurate comparison of the risk of developing cancer between the 
two groups. The exposure to similar disorders and concomitant medications controlled 
for exposures that could have attributed to the risk of cancer development and biased the 
assessment of the cancer risk. Weighting the variables to control the number and 
similarity of variables in the patients in each cohort contributed to the balance of the 
variables between the study participants and results in less bias that could be attributed to 
medical history.  
When assessing cervical cancer risk in SLE patients as compared to non-SLE 
populations, the null hypothesis failed to be rejected. The number of cervical cancers 
found in the non-SLE cohort (n = 88) were significantly greater than the number found in 
the SLE cohort (n = 2). This finding appear to contradict findings by Kiss et al. (2010) 
and Bernatsky et al. (2005), who reported cervical cancer to be increased in SLE patients. 
 The findings may appear to oppose previous findings because of the size of the 
CPRD database versus the sample size used by Kiss et al. (2010) and Bernatsky et al. 
(2005). This study had 3,025 SLE patients and 180, 555 non-SLE patients; Kiss et al. 
(2010) had only 860 patients with SLE and Bernatsky et al. (2005) had only 1,545 
patients with SLE. Both studies compared the rates found in their SLE patients to rates 
found in the general population. In addition, in the Bernatsky et al. (2005) study, they 




Pap testing as compared to non-SLE females. Cervical dysplasia and atypical pap tests do 
not always result in cervical cancer. This study compared only primary cervical cancer, 
not secondary malignancies, nor abnormal Pap tests. This study also compared non-SLE 
females in CPRD only and not in the general population. The patients were also balanced 
in terms of the types of other diagnoses and concomitant medications to which the two 
groups had been exposed. These factors all contribute to the seemingly contradictory 
findings in this study as compared to some previous studies.   
In this chapter, deviations from the initial plan to use preselected covariates based 
upon the literature review were explained along with the rationale for the use of an 
alternative plan. Details of methods used to select and balance the two cohorts from 
CPRD were explained in detail. Checks to ascertain that the models used were included 
to confirm the appropriate fit of the model. Finally, findings from the various assessments 
that were performed to assess the association of cancer development in SLE patients as 
compared to non-SLE patients were presented. In Chapter 5, I will discuss the social 
change implications of these findings, the limitations of this study, and future 
recommendations for continued research to assess the association of cancer development 




Chapter 5: Discussion, Conclusions, and Recommendations 
Introduction 
The purpose of this study was to assess whether there is an association between 
cancer developments in patients with SLE as compared to non-SLE patients. A 
propensity, score-matched, retrospective, cohort study among SLE and non-SLE female 
patients identified in CPRD was used. Female SLE patients were matched with non-SLE 
patients in CPRD. The matching was performed by using a high dimensional propensity 
model. The high dimensional propensity model was used to assign weights to variables 
based upon the analyses of common variables related to SLE and found in the database 
(Schneeweiss et al., 2009). The covariates used to select the SLE and non-SLE cohorts 
were diagnoses that were most commonly made in SLE patients and most commonly 
associated prescriptions made to patients with SLE. The selected covariates were chosen 
based on the frequency that they were found in the database for the selected population, 
in this case SLE. The covariates, concurrent diagnoses and concomitant medications, 
were then assimilated into a propensity score-based confounder adjustment model. The 
application of an IPTW to the SLE and non-SLE cohorts rendered a SLE cohort of 3,025 
and a non-SLE cohort of 180,555 patients.  
Previous research in this area has been based upon small study samples, cohorts 
that were not closed, which could increase the number of patients lost to follow-up, and 
the studies have lacked definitive diagnosis dates for SLE in the participants (Bernatsky 
et al., 2005; Parikh-Patel et al., 2008). As a result, previous studies were generally 




SLE and cancer (Bernatsky et al., 2005). In this study, I used a large, population-based 
database to test the relationship between SLE and cancer.  
Use of the high dimensional propensity model allowed the cohorts in the study to 
be much better balanced than some of the studies that have been done in the past. The 
balance that was created by allowing the computer to search the entire CPRD database 
and select the most common diagnoses and concomitant medications that were assigned 
to patients with a diagnosis of SLE decreased the potential for bias that could result from 
selecting the non-SLE cohort based of age or age group. The balance in matching the 
cohorts decreased the potential for bias that could result due to the use of certain 
medications. The significant finding in the weighted cohorts was that the relative risk of 
developing cancer due to having SLE was 2.74 (95% CL). Another significant finding 
was that age was not a significant factor in whether the SLE patients developed cancer. 
Interpretation of the Findings 
The findings from this study confirm that cancers are increased in patients with 
SLE as compared to persons without SLE. In this study, the greatest number of 
malignancies was female-specific cancers such as breast, uterus, and cervix. The next 
largest group of malignancies was in the digestive system. The cohorts in this study were 
restricted to female only, and for that reason the fact that the greatest types of cancers 
were female-specific can neither confirm nor refute previous findings regarding the types 
of cancers increased in SLE patients.  
As reported by the CDC (2014), age greater than 65 years is a risk factor for most 




including both environmental and lifestyle factors, which are associated with increased 
risk of general cancer development (CDC, 2014). This study could not confirm or 
disconfirm whether age greater than 65 years resulted in a greater risk of developing 
cancer. I did find it increasing that age did not increase the development of cancer. This 
finding is in contradiction to findings by Extermann (2000) who found that increasing 
age increases the likelihood of developing cancer of some type because of the longer 
exposure to potential carcinogens in the environment, foods, and other factors. 
Being overweight increases the risk of some cancers because of increased levels 
of estrogens and insulin (Cancer Research United Kingdom, 2014). OR estimates obesity 
had a 2.5 increased effect on whether cancer developed when all the other variables were 
held constant. A full-term pregnancy before the age of 17 years as compared to a woman 
who had her first pregnancy after the age of 25 years and women who have more than 
three pregnancies were associated with an increase in the risk of cervical cancer 
development (CDC, 2014). These two factors increase the risk of cervical cancer 
development because they increase the chances of acquiring a HPV infection because of 
the potential of the woman having unprotected sex with a greater number of sexual 
partners (ACS, 2014). The hormonal changes associated with pregnancy may also 
contribute to a weakened immune system and render the woman to susceptible to HPV 
infection (ACS, 2014). The OR estimates that if the patient had a pregnancy, she has a 
3.1 (95% CL) increased chance of cancer development when all the other variables were 




pregnancies. For this reason, the ability to assess the impact that pregnancy has on cancer 
development was not possible. 
Use of estrogen-progestagen OCs over a 5-year or greater period may increase the 
development of cervical cancer (CDC, 2014). Although HPV exposure is known to be the 
most important cause of cervical cancer, when combined with long-term use of OCs, the 
RR of cervical cancer development was increased as duration of use increased. Smith et 
al. (2003) studied women with cervical cancer with no history of OC use (RR 1.9-2.2) 
compared to women who had used OCs (RR 1.6-3.9) for more than 10 years and found 
that the incidence of cervical cancer increased with longer use of OCs. OR estimated that 
contraception use had 1.6 increased effects on whether cancer developed, when all the 
other variables were held constant. In this study, the information regarding the amount of 
time that the patient used an OC and whether it was estrogen progestogen-based was not 
assessable; therefore, it is impossible to accept whether OC use affects the risk of cancer 
development. 
Smoking renders a person exposed to many cancer-causing chemicals that affect 
multiple body organs when the chemicals are carried via the blood system to the organs. 
The chemicals act to damage the DNA of cells and may contribute to the development of 
multiple cancers (ACS, 2014). A history of tobacco use was a cancer risk factor in this 
study and was measured as either yes or no. OR estimated that smoking had a protective 
effect on whether cancer developed when all the other variables were held constant. This 
outcome was not expected because it is not consistent with the knowledge base. Neither 




variable appropriately. In this study, the amount of time that the patient smoked was not 
assessable; therefore, it is impossible to accept how smoking affects the risk of cancer 
development based upon the results from this study.  
Limitations of the Study 
The validity of this study depended on the accuracy and reliability of the 
information entered into the database. SLE is a difficult diagnosis to make and there may 
have been a risk of including non-SLE patients. The most common area of bias occurred 
in the collection of history of the patients admitted into the study. The study population 
included females with SLE and female non-SLE patients. Patients with a diagnosis of 
SLE were matched to non-SLE females using a high-dimensional propensity score. This 
method of using a high-dimensional propensity model is one method to address bias that 
can enter a study because of the history of the patients in the comparison groups. This 
method decreased bias that could present itself due to the selection process. A lack of 
consideration to the history of the patients, especially those factors that could lead to the 
development of SLE decreased bias between the comparison groups. The propensity 
score method of matching also addressed bias that was commonly a result of inclusion 
and exclusion criterion for a study. Selection using propensity score matching ensures 
that the comparison groups are equal in their covariates that could lead to the 
development of SLE and cancer.  
The use of data that had already been collected has limitations in that the research 
questions must be tailored around the information that is available in the database. An 




entered into the database were entered with accuracy and reliability. There is no 
expectation that there is a difference in the accuracy of reporting between SLE and non-
SLE patients. The Hospital Episode Statistics database was used for this study. The 
validity of this study depended on the accuracy and reliability of the information entered 
into the database. The most common areas of bias occur in the history of the patients 
admitted into the study, the inclusion criterion used to select patients into the study, and 
the methods used to analyze the study results (Gerhard, 2008).  
Recommendations 
The primary value of this study is that it used a large database to incorporate the 
numerous factors that are thought to lead to the development of SLE and cancer, both 
chronic diseases. There are many challenges in determining associations especially in 
chronic diseases such as SLE and cancer. These two diseases involve multiple factors that 
interact and result in their disease state. Consideration of the various factors that 
contribute to the two diseases is necessary to measure an association of the two diseases. 
The fact that both cancer and autoimmune diseases have been associated with diet, air 
quality, exposure to certain drugs, and personal habits makes the study of an association 
between the two diseases somewhat challenging. Studies completed to date have not 
shown consistent relationships of cancer development in patients with SLE. 
In this study, careful consideration was given to the multiple factors that play a 
role in the development of SLE and in cancer. A large, population-based database was 
used to assess the relationship between SLE and cancer in a large population. The design 




detailed analysis that was easily understood. A propensity score-matched retrospective 
cohort study among SLE and non-SLE female patients identified in CPRD was used to 
assess the association of cancer development in patients with SLE will be conducted. 
Non-SLE patients were matched with SLE patients in CPRD and then linked to an 
additional database for information on the covariates. 
Balance between the SLE and non-SLE cohorts was obtained by using variables 
that were associated with patients with SLE to determine the treatment and non-treatment 
cohorts. This method of cohort selection balanced the SLE and non-SLE cohorts and 
balance between the study participants. I recommend that more studies to assess the 
association of cancer development in SLE patients be conducted utilizing a propensity 
score model to balance the study groups.  
I further recommend that a database that contains more data that can be used to 
assess disease severity be used to study the association of cancer in patients with SLE. A 
focused medical history should be collected so that history such as age at first pregnancy 
and number of pregnancies, use of oral contraceptives, tobacco use, and viruses such as 
EBV/HPV can be assessed. Details of the medical history are essential in studying two 
chronic non-communicable diseases such as SLE and cancer.  
Implications 
Positive social change refers to involvement in activities that make improvements 
in the lives of individuals and communities locally and around the world. The goal of 
social change is to incorporate strategies that allow the individuals in the target 




improvements in the health of the target population as well as their overall quality of life. 
The most important aspect of positive social change is that it gives individuals and 
eventually groups the power to improve the world around them (Walden University, 
2011). My research, to assess the association of cancer development in persons with SLE 
disease, could promote positive social change by providing a better understanding of 
variables that may impact cancer development in patients with SLE. Understanding 
variables that can modify cancer risk can provide insight to factors that could possibly be 
altered to decrease the development of cancer in persons with SLE. 
An understanding of these associations provides valuable insight to factors that 
can be altered to decrease the development of cancer in SLE patients. A matched 
retrospective cohort study among SLE and non-SLE patients was conducted using the 
propensity score methodology to help balance the differences between the comparison 
groups. The propensity score methodology created a similar distribution of observed 
baseline covariates between the two groups. The study outcomes could be used to 
promote positive social change by reinforcing current recommendations for cancer 
screenings in persons with SLE, which could enhance the ability to detect cancer early 
enough to decrease mortality due to cancer in persons with SLE. 
Stronger adherence to cancer screening recommendations could enhance the 
ability to detect a cancer early enough so that treatment can be implemented that may 
result in a higher likelihood to effectively eradicate the cancer and decrease mortality due 
to cancer in persons with SLE. Results from this study could also equips persons with 




regarding their care with a clearer understanding of the cancer risks inherent to persons 
with SLE, particularly when factored with their knowledge of their personal familial risks 
for cancer development.  
Conclusion 
In conclusion, better control of SLE flares has resulted in decreased deaths due to 
SLE activity and people affected by the disease are living longer. The increase in the 
lifespan of people with SLE has now shown that other chronic diseases are often the 
cause of death for persons with SLE. As new models of studying diseases are developed, 
they should be utilized as appropriate. Newer research models can assist in a better 
understanding of the multifactorial causations of chronic diseases since they often are a 
result of overlapping environmental, lifestyle, and everyday exposures. The economic 
burdens caused by autoimmune diseases and cancers make them a major public health 
concern. The increasing health-care burdens of both diseases must be better understood 
so that improved and targeted programs to ease the economic burdens on the public 
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